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CHAPTER 1 
AIMS OF THE THESIS 
Radionuclide therapy 
Neuroendocrine tumours of the digestive tract include two main types of endocrine tumours: 
those developed within the pancreatic islets or the duodenal loop and carcinoid tumours. Most 
neuroendocrine tumours are potentially malignant and have already metastasised at the time of 
diagnosis. The clinical distress of patients with neuroendocrine tumours is related to the 
hypersecretion of h01TI1ones. Somatostatin analogues, of which octreotide is used most commonly are 
of considerable help in controlling symptomatology in these of patients. There is also experimental 
and clinical evidence of tumour growth inhibition in some tumours by somatostatin analogues but the 
mechanism through which this inhibition is exerted is still to be unraveled. A mechanism mediated 
through specific somatostatin receptors could be a possibility since these receptors have been 
identified on most neuroendocrine tumours. 
In vivo visualisation of the somatostatin receptors can be performed with somatostatin receptor 
scintigraphy, which has proven it's clinical value. When used for scintigraphy octreotide is labelled 
with low dose ofIndium-lll C11 In), which emits gamma rays. Theoretically high dose radioactivity of 
1111n could be used for radionuclide therapy since 111In also emits electrons with a short particle range. 
These electrons should be able to damage the nucleus of somatostatin receptor-positive cells. This 
peptide receptor radionuclide therapy with radiolabelled somatostatin analogues could be a promising 
treatment modality for patients with somatostatin receptor-positive tumours. 
Tumour growth after partial hepatectomy 
Partial hepatectomy is perfonned clinically as the only curative treatment modality for liver 
metastases. After partial hepatectomy a well-orchestrated process of liver regeneration takes place 
which enables the liver to restore it's volume. In the rat this regeneration is completed within 10 days, 
in human within 30 days. Clinically, after partial hepatectomy for metastases there are a high number 
of early recurrences. It could be that altered physiological conditions during liver regeneration have a 
tumour growth stimulating effect on non resected remnant tumour cells. If this process of increased 
tumour growth after partial hepatectomy can clinically and experimentally be substantiated, there 
could be a great benefit for systemic adjuvant treatment. However, this adjuvant treatment should not 
impair the process of liver regeneration. 
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Aims of the thesis 
The aims of this thesis were to investigate the possibilities of antitumour treatment with 
octreotide and peptide receptor radionuclide therapy with radiolabelled octreotide in the rat. Therefore 
we used a liver metastases model with somatostatin receptor-positive and somatostatin receptor-
negative tumours. We also studied the tumour growth stimulating effect of liver regeneration after 
partial hepatectomy. Since, if this putative tumour growth stimulation by partial hepatectomy could be 
demonstrated we wanted to see if treatment with octreotide and radionuclide therapy could be 
effective also after partial hepatectomy and whether this treatment would subsequently influence liver 
regeneration. In addition we wanted to investigate the value of somatostatin receptor scintigraphy in 
patients with liver metastases of neuroendocrine tumours to define patients that could possibly benefit 
from peptide receptor radionuclide therapy. 
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CHAPTER 2 
SOMATOSTATIN RECEPTOR IMAGING, THERAPY 
AND NEW STRATEGIES IN PATIENTS WITH 
NEUROENDOCRINE TUMOURS 
Adapted Jrom: 
The British Journal oj Surgery 2001; 88: 31-40 
G.D. Slooter, A. Mearadji, W.A.P. Breeman, 
M. de Jong. E.P. Krenning and c.H.J. van Eijck 
Somatostatin receptor expression 
Somatostatin (SS) is a small regulatory peptide; it was isolated in the ovine hypothalamic 
gland in 1973 as growth honnone (GH) releasing inhibiting factor l . Somatostatin is widely distributed 
in the human body and is found not only in the hypothalamus, but also in various parts of the 
gastrointestinal tract, indicating that inhibition of GH is not its only function2• Apart from its function 
as neurotransmitter in the central nervous system (CNS), it also has inhibitory effects on the secretion 
of honnones by pancreatic islands (insulin, glucagon) and on the exocrine pancreatic function. 
Somatostatin also inhibits n01mal gastrin production and consequently gastric acid and pepsin 
production3• A number of observations have also suggested an antiproliferative effect of somatostatin 
and its stable analogues4-6• 
Figure 1 The amino acid sequences of 
native and synthetic, metabolically stable 
somatostatin analogues. (Image byT. van Os) 
Somatostatin-28 
30matostatin-14 
Octreotide 
(3M3201-995) 
lanreotide 
(BIM23014) 
Vapreotide 
(AC-160) 
Seglitide 
(MK678) 
Critical to all these actions is the expression of 
somatostatin receptors (SS-Rs) on the cell 
membrane. These SS-Rs subserve two functions: 
first to recognize the ligand and bind it with high 
affinity and specificity, and second to generate a 
transmembrane signal that evokes a biological 
response. Large number of SS-Rs are found on 
most tumours with amine precursor uptake and 
decarboxilation (APUD) characteristics and 
neuroendocrine properties, such as carcinoids, 
paragangliomas, pheochromocytomas, medullary 
thyroid cancers and endocrine pancreatic tumours. 
In addition large numbers of binding sites with 
high affinity for somatostatin were also found on 
breast and brain tumours as well as on vanous 
cells of the immune system7-][). At least five 
different human SS-R subtypes have been 
cloned 11 . All subtypes bind somatostatin with high 
affinity, while their affinities for the somatostatin 
analogue SMS 201-995 (Octreotide) differ 
considerably. Octreotide binds with high affinity 
to SS-R subtype 2 (sst2) and sst5, to a lesser degree 
to sst), while no binding to sStl and SS4 occurs. 
Other somatostatin analogues that are in clinical 
use such as BIM 23014 (Lanreotide) and RC-160 
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(Vapreotide) as well as the hexapeptide MK678 (Seglitide) bind to three to five SS-R subtypes 
displaying also high affinity for sst2 and sst5 and moderate affinity for sst312. Figure 1 shows the amino 
acid sequences of native somatostatin and these analogues. Somatostatin receptor messenger RNA 
subtypes are widely expressed in neuroendocrine tumours, but their distribution does not necessarily 
correlate with SS-R subtype expression. Furthennore SS-R subtypes show a differential subcellular 
localisation in human SS-R positive tumours 13. The majority of human endocrine pancreatic tumours 
such as gastrinomas, glucoganomas, VIPomas and "non-functioning" islet cells tumours express sst2. 
In vitro studies have shown that 72 per cent of the insulinomas express SS-Rs, however, these 
receptors are mainly st3, which has low affinity for octreotide14JS. Although SS-Rs have been 
demonstrated on exocrine pancreatic cells in experimental animals (mainly on the acinar cells), neither 
SS-Rs nor neuroendocrine properties could be confinned on human exocrine pancreatic 
adenocarcinomas16. Carcinoids, paragangliomas, pheochromocytomas and medullary thyroid cancers 
all have a mixed distribution of the SS-R subtypes but sst2 is expressed most frequently. The presence 
of different combinations of SS-R subtypes may explain the variable clinical response to somatostatin 
analogues and the difference in successful localisation by SS-R scintigraphy (SRS) of these tumours. 
Metastases of SS-R positive tumours initially express also these receptors, however loss of these 
receptors has been described after dedifferentiation of tumour cells or after chemotherapy17. In 
addition, SS-R overexpression was identified in peritumoural veins of primary tumours and in veins 
surrounding lymph node, bone and lung metastases IS. 
Somatostatin receptor scintigraphy 
The optimal management of patients with neuroendocrine tumours requires accurate imaging 
and staging. For the visualisation of SS-R positive tumours SRS with C llIndium_ 
diethylenetriaminopenta-acetic acid (lllIn_ DTPAo)]octreotide (Octreoscan®) has been used for more 
than 10 years 19.20. The efficacy of SRS using [1 1 lIn-DTPAo]octreotide in patients with histologically or 
biochemically proven endocrine pancreatic tumours or carcinoids was evaluated in a European 
multicenter trial21 • The highest success rates of SRS were observed with glucagonomas (100 per cent), 
VIPomas (88 per cent), gastrinomas (73 per cent),"non-functioning" islet cells tumours (82 per cent) 
and carcinoids (87 per cent). Insulinomas were detected in only 46 per cent of cases due to the low 
incidence of sst2 on insulinoma cells. The low sensitivity in this study found for some tumours may be 
related to important difference in scanning procedures such as the amount of radioligand administered, 
the duration of the acquisition and the use of single photon emission computed tomography 
(SPECT)22. With SPECT, in which a rotating camera is used, image reconstructions can be made 
similar to spiral computed tomography (CT). This technique gives additional visual infonnation, 
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especially on tumours in the liver and upper-abdomen23 • Twenty-five per cent more liver metastases 
are detected with SPEer than with planar SRS. 
In a prospective study comparing the sensitivity of SRS with that of CT, magnetic resonance 
imaging (MRI), ultrasonography and selective angiography in the detection of primary and metastatic 
gastrinomas, SRS altered clinical management in 47 per cent of instances and had a superior 
sensitivity, and specificity24 (table 1). 
Table 1 Imaging methods for the detection of liver metastases and extra-hepatic metastases in 
patients with Zolinger-Ellison syndrome 
Positive result (%) 
Extra-hepatic tumour Liver metastases 
Procedure (n ~ 80) (n ~ 24) 
Ultrasonography (US) 9 46 
Computed tomography (CT) 31 42 
Magnetic resonance imaging (MRI) 30 71 
Angiography (Angio) 28 62 
US + CT + MRI + Angio (CIM) 48 83 
SRS 58 92 
SRS + CIM 68 96 
SRS Only* 20 12 
elM Only** 10 4 
Gibril eta!. Ann Intern Med 1996; 125:26-34 
Results are expressed as the percentage of the 24 patients with proven liver metastasis and of the 80 with 
extrahepatic disease. Conventional imaging methods (ClM) included ultrasonography, computed tomography 
(CT), magnetic resonance imaging (A1Rl) and angiography. 
* Tumour detected only with somatostatine receptor scintigraphy (SRS) 
** Tumour detected only with CIM 
Cadiot et a!. compared the results of SRS with those of conventional imaging techniques including 
endoscopic ultrasonography, and with surgical findings in 21 consecutive patients with Zollinger-
Ellison syndrome25 • SRS added complementary information to other imaging techniques including 
echoendoscopy and improved the preoperative detection of extrapancreatic gastrinomas. By 
combining SRS with echoendoscopy they were able to detect 90 per cent of the tumours in the upper 
duodenopancreatic area. SRS identified metastatic disease in 20-30 per cent of patients after all other 
imaging techniques had failed23 • In another study of 160 patients with biologically andlor 
histologically proven gastroenteropancreatic tumours, including pancreatic islet cell tumours, SRS 
changed the surgical therapeutic strategy in 40 patients (table 2) 26. 
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Table 2 Clinical impact of somatostatin receptor scintigraphy (SRS) in 160 patients with 
gastroenteropatic tumours. 
Initial Classification 
No metastasis 
II Only liver metastasis 
III Extra-hepatic metastasis 
Total no. 
90 
59 
11 
Leblah! el ai., J Nue! Med 1997:38;853-858 
SRS Classification 
II 
7 
46 
III 
18 
13 
11 
Unsuspected liver tumours were discovered only by SRS in seven patients, contralateral1iver tumours 
before hepatectomy in two, and extrahepatic disease in 31 patients. 
Finally, difference in SS-R expression between islet cells tumours, especially "1100-
functioning" tumours and pancreatic duct cancers offers the possibility of differentiating behl{een 
these tumours preoperatively27, This is important, as palliative surgery in patients with islet cell 
tumours is of value not only in relieving clinical symptoms, but also in decreasing tumour burden, 
which might enhance the effect of medical treatment and result in improved clinical status and longer 
survival. 
Clinical use of somatostatin analogues 
Most endocrine pancreatic tumours, with the exception of insulinomas, have a malignant 
potential and have already metastasised at the time of diagnosis. These tumours are in general slow 
growing and most of the clinical distress is related to the hypersecretion of honnones, which often 
incapacitates the patient and causes long and repeated periods of admission to hospital. The clinical 
use of the somatostatin analogue octreotide in this type of patients is of considerable help in 
controlling symptomatology. Debilitating diarrhea, dehydration and hypokalemia (VIPoma) and 
necrolytic skin lesions (glucagonoma) can be well controlled during chronic treatment with octreotide. 
There is no doubt that octreotide therapy is of great benefit for most of these patients and improves 
their quality of life dramatically2S. In selected patients peptic ulceration and hyperplasia of fundic 
agyrophil cells (gastrinoma ) or life-threatening attacks of hypoglycemia (metastatic insulinoma) 
octreotide could be of therapeutic benefit29.30. Clinical studies in those with honnone producing islet 
cell tumours have shown a close parallel between the presence of SS-Rs on the tumours and the in vivo 
and in vitro suppressive effects of octreotide on honnone release31 . This indicates that SRS can predict 
a possible suppressive effect of octreotide on honnonal hypersecretion by endocrine pancreatic 
tumours. Although octreotide is able to inhibit gastrin release in Zollinger-Ellison syndrome, protoll-
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pump inhibitors are currently the first choice as over 80 per cent of patients are controlled by 
omeprazole, lanzoprazole or pantoprazole. A major problem in the treatment of patients with islet-cell 
tumours and carcinoids with octreotide is that the inhibition of the secretion of tumour related 
hormones is transient. Most patients become insensitive to octreotide treatment, possibly by 
downregulation of SS-R expression or outgrowth of SS-R-negative clones6J2J3. The beneficial effects 
on clinical symptomatology in patients with metastatic endocrine pancreatic tumour and carcinoids are 
highly variable. Increasing the dose of octreotide or intennittent administration reverses these 
problems in most patients. The median duration of improvement of diarrhoea and flushing attacks by 
octreotide in patients with metastatic carcinoid disease is over 12 monthss . 
Oncologic applications of somatostatin analogues 
The observation that somatostatin inhibits the release of various peptide hormones has 
stimulated interest in its use as an antiproliferative agent. In pre-clinical studies somatostatin 
analogues have inhibited the growth of a wide variety of SS-R-positive as well as SS-R-negative 
tumours in vivo and in vitro4.6.34.36. An indirect tumour growth inhibition may be achieved via the 
inhibition of circulating tumour growth-promoting circulating hOffi1ones COH, insulin-like growth 
factor I, insulin) and inhibition of circulating, paracrine- and/or autocrine-secreted stimulatory growth 
factors. Somatostatin and it's analogues can also modulate the activity of immune cellsJ7 and 
potentially influence tumour blood supply; Reubi et al. demonstrated a high density of SS-Rs on veins 
in the peritumoural zone of several types of malignant tumour3S . A potentiation of the antiproliferative 
effect of octreotide has also been suggested39, but no beneficial effect of octreotide combined with 
tamoxifen was found in patients with metastatic breast cancer40. Critical to the direct antiproliferative 
effects of somatostatin analogues could be the presence of SS-Rs. Both cAMP-dependent and -
independent effector mechanisms have been suggested6.41-44, while stimulation of phosphotyrosine 
phosphatase activity may play an important role in the inhibition of growth factor-stimulated cell 
growth45-47. The results of clinical trials in patients with GEP tumours, using somatostatin analogues 
alone or in combination with interferon-a, are rather disappointing with a biochemical response in 77 
per cent of patients with a median duration of 15 months but without any reduction of tumour size48 . 
Clinically, octreotide has been the most commonly applied somatostatin analogue, yielding 
biochemical response rates of between 30 and 70 per cent but objective tumour shrinkage in less than 
10 - 15 per cent of patients5.49-ss. Treatment with standard doses of the somatostatin analogue 
lanreotide does not appear to be any better than with standard doses of octreotide. However, tumour 
biopsies before and during treatment with high doses of lanreotide have indicated apoptosis in 
responding patients56.s8. Side effects of long-tenn administration of somatostatin analogues are rare. The 
most relevant side effect is the development of gallstones, which is believed to derive from the inhibition 
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of gallbladder emptying due to the inhibition of cholecystokinin release59. Octreotide might also influence 
blood sugar levels in patients with diabetes mellitus. 
Peptide Receptor Radionuclide Therapy 
A fascinating application could be the use of radiolabelled octreotide for Peptide Receptor 
Radionuclide Therapy (PRRT). Systemic injection of [IIIIn-DTPAo]octreotide for SRS results is a long 
retention time of radioactivity in the tumours. After binding to the SS-R the ligand-receptor complex is 
internalised through invagination of the plasma membrane60. The radio ligand is transported and delivered 
into the lysosomes61 and the receptor then recycles back to the plasma membrane. This process is 
temperature dependent and takes approximately 15 min60 and a single receptor can deliver numerous 
ligand molecules to the lysosomes6.62.63. The metabolite I IIIn-DTPA-D-Phe is not capable of passing the 
lysosomal membrane resulting in a biological half-life of in human tumour tissue of> 700 hours61.64.65. 
JilIn not only emits gamma-rays, which can be visualised during scintigraphy, but also internal 
conversion- and Auger electrons having a medium to short tissue penetration (200-550 f.un, 0.02-10 ).tm, 
respectively). Therefore, an effect on trnnour cell proliferation could be expected, as the radiotoxicity of 
the radionuclide is very high if the DNA of the cell is within the particle range after internalisation66.67 . 
Our hypothesis was that the same agent rJllIn-DTPAo]octreotide that is used in SRS with a low 
radioactive dose could be used for radionuclide therapy when given with a high radioactive dose. 
Figure 2 
INTERNAL CONVERSION 
(~. convecs;on electron @ aUge~electron (~~ 
111 In 
Schematic representation of gamma-ray emission ("internal conversion'') leading to the 
ejection of conversioll-electrons (nuclear photons transfer their energy to orbital 
electrons. which are then ejected/rom the atom. theraby leaving an electron vacancy. 
indicated with the small open circle) alld Auger-electrons (the latter b); X-ray photon 
interaction with an loosely bound outer electron). 
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CHAPTER 3 
SOMATOSTATIN RECEPTOR DEPENDENT GROWTH 
INHIBITION OF LIVER METASTASES BY 
OCTREOTIDE 
BrilishlournaloJSurgeTY 1994; 81: 1333-1337 
C.H1. van Eijck, G.D. Siooler, L.1. Hofland, W Kart, 
1. leekel, S. W1. Lamberts and R.L. Marquet 
Abstract 
Rats were administered the somatostatin analogue octreotide 15 )lg intraperitoneally twice daily 
for 4 weeks after intraportal injection of somatostatin receptor-positive pancreatic tumour cells (CA-
20948) and somatostatin receptor-negative colonic tumour cells (CC-531). Octreotide significantly 
inhibited the growth and development of somatostatin receptor-positive tumour cells in the liver. The 
median number ofliver tumours was 286 (range 146 to greater than 500) in the treated animals and morc 
than 500 (range 250 to in 3 excess of 500) in the controls (p< 0.05). This significant difference in tumom 
load was also represented in the mean (s.e.ill.) liver weight (l4.5±3.7) g in animals given octreotide 
versus 17.9±3.0) g in the controls). No effect of octreotide treatment was found on the growth and 
development of somatostatin receptor-negative tumour cells in the liver. The median (range) number of 
tumours was 6.5 (0-425) in the treated animals and 11.0 (0-475) in the controls. Mean (s.e.m.) liver 
weights were 14.0±5.7) g and 11.8±4.5) g respectively. There was no difference in senJm levels of growth 
honnone, prolactin and insulin-like growth factor between control and octreotide treated rats. The growth 
inhibition of somatostatin receptor-positive tumour cells was unlikely the result of suppressed secretion of 
one of these tumour growth factors. Octreotide may be useful for treatment of patients with somatostatin 
receptor-positive hepatic metastases, which can be demonstrated by somatostatin receptor scintigraphy. 
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Introduction 
Several possible mechanisms of action have been postulated for the tumour growth-inllibitory 
effect of somatostatin analogues on different tumours l . ll . Schally et al. in 1987 demonstrated that the 
reduction of circulating levels of prolactin and growth honnone by somatostatin might contribute to the 
inhibition of breast and prostate nunour growth l2. Moreover, somatostatin may inhibit local gro\\-1h factor 
activity, as grow1h honnone stimulates cell differentiation directly and clonal expansion indirectly through 
local production of insuline-like growth factor I3- 16• Somatostatin can also have a direct antiproliferative 
effect and, furthennore, by preventing centrosomal separation inhibits the DNA synthesis and cell 
replication induced by epidermal gro\vth factor (EGF)17. In human pancreatic cancer cells, somatostatin 
activates dephosphorylation of EGF receptors and thereby reverses the stimulatory effect of EGF on cell 
growth lKl9, Other possible mechanisms by which somatostatin analogues may inhibit tumour growth are 
interference with the secretion of autocrine growth factors by tumour cellsI7.20.21 and direct inhibition of 
angiogenesis22.23. An increase in natural killer cell activity in humans24 and stimulation of the activity of 
the reticuloendothelial system in rats have been reported following treatmnet with somatostatin analogues. 
These effects indicate that a change in ilmnunological activity may also partly explain the inhibitory 
effects on tumour gro\vth9. Octreotide significantly reduces the growth of tumour in the liver following 
intraportal injection of Walker cells in rats but has no effect on the growth of tumours after injection of 
these cells into the thigh. This finding was explained by postulating a stimulatory effect of octreotide on 
the reticuloendothelial system and/or a reduction in hepatic and tumour blood flOW25 . Another 
somatostatin analogue (RC-l60) also significantly inhibited the incidence and growth of liver metastases 
of colonic 320 DM and WidR human colonic cancer cells in nude mice26, 
A technique for the in vivo visualisation of somatostatin receptor-positive endocrine tumours and 
their metastases has recently been developed. A parallel between the presence of somatostatin receptors 
on tl1lTIOurS and the in vivo and in vitro effects of octreotide on honnonal release from these tumours was 
found, suggesting that a positive scan predicts a good suppressive effect of somatostatin analogues27. The 
present study therefore investigated whether the growth and development of hepatic metastases could be 
inhibited by octreotide, whether this was related to the presence of somatostatin receptors on the tumour 
cells and whether this was the result of inhibition of putative tumour growth factors. 
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Materials & Methods 
Animals 
Thirty-two male rats weighing 250-300g of the inbred WAG and Lewis strains were studied. The 
animals were bred under specific pathogen-free conditions and were 10 to 14 weeks old when used. They 
were kept under standard laboratory conditions (12-h light-dark cycle) and fed a standard laboratory diet 
(Hope Fanus, Woerden, The Netherlands). The experimental protocols adhered to the rules laid down in 
the Dutch Animal Experimentation Act and were approved by the Committee on Animal Research of the 
Erasmus University, Rotterdam. 
Tumours 
CC-531 is a 1,2-dimethylhydrazine-induced, moderately differentiated colonic adenocarcinoma 
that is transplantable in syngeneic WAG rats1S . The tumour was maintained in vitro in RPMI 1640 
medium supplemented with 5 per cent fetal calf serum (virus and mycoplasma screened), I per cent 
penicillin 5000 units/ml, I per cent streptomycin 5000 units/ml and I per cent L-glutamine 200mmolll (all 
supplements obtained from Gibco, Breda, The Netherlands). Before their use cells were trypsinised (5 
min,37°C), centrifhged (5 min at 700g), resuspended in RPM! 1640 and cOlmted before use. Viability was 
measured with trypan blue exclusion (0,3 per cent in a 0,9 percent sodium chloride solution) and always 
exceeded 95 per cent. The tumour is immunogenic as determined by the immunisation challenge 
method29• 
The pancreatic tumour, CA-20948, which was derived from Dr. KlijnJ , was originally induced by 
azaserine. The hllnour is of acinar origin and is maintained in the authors laboratory as a transplantable 
tumour in Lewis rats. The tumours were removed from the rats, washed in ice-cold RPMI 1640 
supplemented with antibiotics, and chopped into small fragments which were passed through a 18-G 
needle. The resulting sluny was incubated for 10 min in RPMI 1640, centrifliged at 500 g for 5 min and 
washed twice with cold medium. 111e peliet was resuspended and adjusted to a suspension containing 
200xl 06 live cells per mi. 
Somatostatin receptor binding studies 
Reaction conditions were the same as those described by Reubi30. The radioligand used in the 
binding studies was the radiolabelled somatostatin analogue C25 I_ Tyr3]octreotide (SMS 204-090; Sandoz, 
Basel, Switzerland). Briefly, membrane preparations corresponding to 50).lg protein ofCC-531 colonic 
and CA-20948 pancreatic tumour cells were incubated in a total volume of 100 ).ll RPMI at room 
temperature for 90 min with 30000-50000 c.p.m. radio ligand and increasing concentrations of unlabelled 
TyrJ-octreotide in HEPES buffer lOmmolll HEPES, Smmol/l MgCl, and O,2g/1 bacitracin, pH 7,6) 
containing 0,2 per cent bovine sennll albumin. Ice-cold HEPES buffer (l mI, pH 7,6) was added to the 
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assay mixture after the incubation, and membrane-bound radioactivity was separated from unbound by 
centrifugation during 2 min at 14000 r.p.m. in a microcentrifuge31 . The remaining pellet was washed twice 
with ice-cold HEPES buffer, and the final pellet was counted in a y counter. Specific binding was taken to 
be total binding minus binding in the presence of 10 ~moll1 unlabelled Tyr"-octreotide. Unrelated 
compounds, such as thyrotropin-releasing honnone, luteinizing honnone-releasing honnone and EGF, 
added in a 1000-fold excess were not able to displace [125I~Ty?]octreotide binding. Somatostatin receptor 
binding data were analyzed by Scatchard pl022. 
Induction and measurement of liver metastases 
Metastatic tumours in the liver were established for both cell lines in 16 rats. A 2.5 cm median 
abdominal incision was made in each rat after induction of anaesthesia and 1.2x106 viable CA-20948 cells 
in 0.6 ml Hank's balanced salt solution (HESS) or 5xl05 CC-531 cells in 0.5 ml HBSS were injected 
slowly into the portal vein. The abdominal wall was closed with one layer of continuous silk suture. The 
rats were divided into groups after injection of tumour cells: group 1, CC-531 liver metastases treated with 
octreotide (eight WAG rats); group 2, CC~531 liver metastases used as controls (eight WAG rats); group 
3, CA-20948 liver metastases treated with octreotide (eight Lewis rats): and group 4, CA-20948 liver 
metastases used as controls (eight Le\vis rats). All rats were killed by an overdose of ether after 28 days 
for evaluation of the incidence of liver metastases. The livers were excised and fixed in 10 per cent 
fonnalin overnight. The visible tumours on the surface of each liver (up to 500) were counted and scored 
and, finally, all livers were weighed. 
Treatment with the somatostatin Gna/ogue octreotide 
Octreotide (D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-ol) (Sandoz) 15 ~g was injected 
intraperitoneally twice daily (approximately 50 I.I..g/kg) starting on the first day after tumour implantation 
in rats of groups 1 and 3. The dose of octreotide was chosen on the basis of a previous study33 on the 
effects of octreotide on growth of 7315a pituitary tumour cells in rats. 
Assays 
Plasma of 16 rats (eight controls and eight treated with octreotide) was collected 4, 11 and 18 
days after starting the administration. Prolactin and growth honnone concentrations were detennined by a 
double antibody radioimmunoasay, as described previously"4.35. Concentrations of IGF-l were measured 
by radioimmunoassay using a commercially available kit from Medgenix Diagnostics (Brussels, 
Belgium). 
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Statistical analysis 
All data are expressed as means (s.e.m.). Statistical analysis was performed using the Mann-
\Vhitney U-test. P<0.05 was considered significant. 
Results 
Somatostatinreceptor binding studies 
Specific binding of the 125I_Iabelled somatostatin analogue Ty~-octreotide to membrane 
preparations of CA-20948 pancreatic tumour cells was demonstrated, but not to the CC-531 colonic 
tumour cells (figure 1). Binding C25I-Tyr3]octreotide to CA-20948 membranes could be displaced in a 
dose-dependent manner with unlabelled Ty~-octreotide. Scatchard analysis of these data revealed a single 
class of high affinity binding sites with an apparent dissociation constant (Kd) of 0.6 nmo1!1 and a 
maximum binding capacity (Bma.,) estimated to be 110 fmol per mg per membrane protein (table 1). 
Figure 1 
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Dose dependent displacement of (51-Tyr'joctreotide binding to membranes of rat brain cortex 
(.""), CA-20948 pancreatic (0) and CC-531 cololl (t.) tumour cells by unlabelled TYI}-octreotide. 
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Table 1 Dissociation constant (KJ) and maximum binding capacity (Bmu» of 
somatostatin receptors. 
Cell type 
CA-20948 
CC-53 I 
Brain cortex (control) 
Il.d.:not defee/able 
KJ(nmolll) 
0.6 
n.d. 
1.2 
Bmu (fmol per mg membrane protein) 
110 
n.d. 
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E;[fect of oct reo tide on the incidence of liver metastases 
i}( /1 
The number of hepatic metastases of CA-20948 pancreatic tumour cells was significantly reduced 
after 28 days of treatment with octreotide. The median number of liver tumours was 286 (range 146 to 
greater than 500) in treated rats and more than 500 (range 250 to in excess of 500) in controls (P<0.05). 
This difference in tumour load also recurred as a difference in mean (s.e.m.) liver weight (14.5 (3.7) g in 
animals given octreotidc and 17.9 (3.0) in controls) (table 2). Regression analysis of liver weight and the 
number of metastases produced a correlation coefficient of 0.95 (P<O.OI). Rats injected with colonic 
tumour cells (CC-53I) showed no significant difference in the number of liver tumours (median (range) 
6.5 (0 - 425) in the treated animals and 11.0 (0 - 475) in the controls) and the mean (s.e.m.) liver weight 
(14.0 (5.7) g in the treated animals and 11.8 (4.5) in the controls). 
Table 2a Liver weight and incidence of hepatic metastases ofCA-20948 and CC-531 
cancer cells treated with octreotide. 
Treatment 
CA-20948 
Controls (n~8) 
Octreotide (n=8) 
CC-531 
Controls (n=8) 
Octreotide (n=8) 
Liver weight (g) 
Mean (s.e.m.) 
17.9 (3.0) 
14.5 (3.7)" 
11.8 (4.5) 
14.0 (5.7)" 
Number of tumours 
Median (range) 
>500 (250->500) 
286 (146->500)' 
11.0 (0-475) 
6.5 (0-425)'" 
·P<O.05, "/lot significant (versus controls. Mann-Whitney U test) 
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Table 2b Incidence of hepatic metastases ofCA-20948 and CC-53 1 cancer cells treated with 
octreotide. 
Treatment 
CA-2094S 
Controls (0=8) 
Octreotide (n~S) 
CC-S31 
Controls (n~S) 
Octreotide (n=8) 
~umber of metastases 
0 
0 
0 
2 
2 
1-100 
o 
o 
4 
3 
100-S00 
3 
7 
2 
3 
>500 
S 
o 
o 
Effects qf octreotide on growth hormone (GH), prolactin (PRL) and IGF-l release 
Plasma levels of growth hormone, proiactine and IGF-I were not affected by chronic 
administration of octreotide (table 3). 
Table3 Effect of octreotide on plasma honnone levels. 
Prolactine (~g!I) Growth hormone (!-lg/l) IGF-I (nnmoIlI) 
Day 4 
Controls (0=8) 12.4 (S.6) 10.4 (6.3) 10S.0 (11.5) 
Octreotide (0=8) 11.4(S.I) 9.5 (6.7) 99.S (10.6) 
Day II 
Controls (0=8) 9.6 (6.4) 3.4 (1.7) IOS.9 (11.0) 
Octreotide (0=8) 11.7 (7.5) 2.S (2.0) 100.9 (10.7) 
DaylS 
Controls (n~S) 10.3 (6.9) S.6 (4.0) 103.S (11.6) 
Octreotide (n~S) 9.7 (7.1) 5.1 (3.1) 92.1 (13.3) 
Values are means (s.e.m.) 
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Discussion 
Several studies have demonsn'ated that somatostatin analogues inhibit tumour gmwth in 
experimental tumour models l -9, Most tumotITs used in these experiments contain somatostatin receptors 
and were studied in vitro and ill vivo in transplantable lesions, Nott et al. reported the effects of octreotide 
pretreannent on hepatic tumour derived from inn'aportal administration of Walker cells1o.25 , They 
suggested that the inhibitory effect of octreotide was related to the location of the Walker cells within the 
liver. as the somatostatin analogue stimulated the activity of the hepatic reticuloendothelial system by 300 
per cent. Kupffer cells and large granular lymphocytes fonn an important natural defence against 
malignant cells in the liver, Reduced portal venous flow and splanchnic vascular resistance in octreotide-
treated animals, both of which decrease the supply of nutrients in the early stages of development of 
hepatic tumotIT, were also noted by these authors25, The somatostatin analogue RC-J60 was also found to 
inhibit the incidence and grO\yth of liver metastases from nyO human colonic cancers as demonstrated by 
a reduced 5-bromo-2'-deoxyuridine labelling index, and DNA and protein content of the tumotIT, 
suggesting a cytostatic effect ofRC-160 on cellular proliferation26, 
Another possible mechanism of the antitumour action of somatostatin analogues includes the 
interference with secretion of growth factors such as prolactin, growth honnone and IGF-l. The reduction 
in prolactin levels produced by the administration of octreotide in animals may contribute to the inhibition 
of the grO\vth of experimental breast and prostate tumotITs 12. The fall in growth honnone levels could also 
directly or indirectly be of importance for growth inhibition of various tumotITs. Secretion ofIGF-l, which 
mediates most of the effects of growth honnone at tissue levels and also induces differentiation and 
proliferation of mesenchyme derived celis, is also indirectly inhibited by somatostatin analogues 13-16. A 
decrease in the concentration of IGF-l or suppression of its activity might therefore reduce or prevent its 
mitogenic effects shown in vitro. 
The results of the present study demonstrate that octreotide significantly reduces the growth and 
development of hepatic tumotITs induced by intraportal injection of somatostatin receptor-positive CA-
20948 pancreatic celis, but not of somatostatin receptor-negative CC-531 colonic cells. As no difference 
was found in serum levels of prolactin, grO\yth honnone and IGF-l during treatment with the somatostatin 
analogue, and no inhibition of growth of somatostatin receptor-negative CC-531 hepatic metastases was 
observed, the mechanism by which growth of CA-20948 tumotIT cells is inhibited may be somatostatin 
receptor dependent and may not be dependent on stimulation of the reticuloendothelial system or a 
reduction in portal flow. If immunomodulation had taken place, growth inhibition of CC-531 cells should 
have occured as this tumotIT is weakly immunogenic36,37 and susceptible to immunomodulation. 
Recently the authors described the use of isotope labelled somatostatin analogues for the 
visualisation of neuroendocrine tumours and their metastases27. In vitro detection of somatostatin 
receptors on these tumours indicated that ligand binding to the turnOtIT in vivo represents binding to 
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specific somatostatin receptors. The identification of such receptors predicted a good suppressive effect of 
octreotide on hormonal hypersecretion by these tumours. The results of the present study indicate that 
octreotide might be considered as a useful agent for the treatment of patients with somatostain receptor-
positive liver metastases from neuroendocrine tumours, particularly since no side-effects have been 
observed in patients given octreotide38• 
In conclusion, the somatostatin analogue octreotide inhibits the growth and development of 
hepatic tumours of somatostatin receptor-positive CA -20948 pancreatic cells. Although other mechanisms 
can not be ruled out the present findings suggest that this may be mediated via a somatostatin receptor 
dependent mechanism, as nO inhibition of somatostatin receptor-negative CC-531 colonic cells was found 
and no differences in levels of circulating hormones and growth factors were observed. Additional in vivo 
studies with tumours of different somatostatin receptor expression are needed to confirm this notion. 
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CHAPTER 4 
THE ANTIPROLIFERATIVE EFFECT OF 
RADIOLABELLED OCTREOTIDE IN A METASTASES 
MODEL IN THE RAT 
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Abstract 
Most neuroendocrine tumours and several other tumours such as breast carcinoma and malignant 
lymphoma express somatostatin receptors (SS-R). Lesions expressing these receptors can be visualised by 
receptor [IIIIndium-diethylenetriaminopenta-acetic acid ell 1n- DTPA o)]octreotide (Octreoscan®) 
(C11ln-DTPAo]octreotide). This radioligand is intemalised and transported to the lysosomes with a long 
residence time of III In. The aim of this experimental study in rats was to investigate whether the same 
agent, given in a high radioactive dose, can be used for therapy of hepatic metastases of different tumour 
cell lines. The development of hepatic metastases was determined 21 days after direct injection of SS-R-
positive or negative tumour cells into the portal vein in rats. On day 1 and/or 8 the animals were treated 
with 370 MEg (0.5 ,Llg) C"In-DTPAoJoctreotide. In one experiment, using SS-R-positive tumour cells, 
animals were pretreated with a high dose of "cold" octreotide to block the SS-R by saturation. The number 
of SS-R-positive liver metastases was significantly decreased after treatment with [I iI In-
DTPAo]octreotide. Blocking the SS-R by octreotide substantially decreased the efficacy of treatment \\lith 
C IIJn_DTPA o]octreotide, suggesting that the presence of SS-R is mandatory. This was confirmed by the 
finding that the number of SS-R-negative liver metastases was not affected by treatment with ell In-
DTPA o]octreotide. Therefore we conclude that: (l) high radioactive doses with C llln_DTPA o]octreotide 
for PRRT (peptide receptor radionuclide therapy) can inhibit the growth ofSS-R-positive liver metastases 
in an animal model, (2) PRRT is only effective ifSS-R are present on the tumours, (3) the effect ofPRRT 
\vith [lllln_DTPA °Joctreotide can be reduced by pretreatment with "cold" octreotide, which indicates that 
receptor binding is essentail for PRRT. Our data suggest that PRRT with radiolabelled octreotide might be 
a new promising treatment modality for SS-R-positive tumours. 
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Introduction 
Somatostatin is a small regulatory peptide which inhibits the release of various honnones and 
may act as neurotransmitter in the central nervous system l • A number of observations have also suggested 
an antiproliferative effect of somatostatin and its analogues2-4. Critical to these actions of somatostatin is 
the presence of somatostatin receptors (SS-Rs). SS-Rs have been demonstrated on a variety of human 
tumours and their metastasess. At least five different human SS-Rs subtypes (sst l_S) have been cloned6. All 
subtypes bind somatostatin with high affinity, while their affinity for the somatostatin analogue octreotide 
differs considerably. Octreotide binds 'with high affinity to sst2 and sst5 and to a lesser degree sst3, while 
no binding to sstl and ss~ occurs. However, the vast majority of human SS-R-positive tumours express 
sst2 '. After the injection of [IIIIn_DTPAo]octreotide SS-R-positive tumours show uptake of radioactivity 
that can be visualised with a gamma cameraR.'1. IllIn not only emits gamma rays, which can be visualised, 
but also internal conversion- and Auger electrons ,,\-'ith a medium to short tissue penetration (200-550 I-1m. 
0.02-10 I-1m, respectively)I().12. fl1 vivo IllIn is internalised and tTansported into the lysosomes of SS-R-
positive cells after the administration of C"ln-DTPAIl]octreotide13 with a long residence time in the 
tumour (biological half-life> 700 hourS)14. Therefore, an effect on tumour cell proliferation by these 
electrons may be expected. Inspired by the ample knowledge of [I II In-DTPAo]octreotide scintigraphy, 
peptide receptor radionuclide therapy (PRRT) with high doses of radioactivity labelled with this SS 
analogue has been initiated clinically14-16. In addition, three experimental studies demonstrated tumour 
gmwth inhibitory effects on solid subcutaneous tumours by radio labelled somatostatin analogues in 
animal models 17-19. This new concept of SS-R mediated. PRRT however, has never been tested for the 
treatment of SS-R-positive liver metastases with an 1!IIn-labelled somatostatin analogue. In a previous 
repoli \ve demonstrated that grov.rth ofSS-R-positive CA-20948 pancreatic tumour cells in the liver could 
be inhibited by subcutaneous administration of 15 ~g "cold" octreotide novice per day, whereas no effect 
was achieved with SS-R-negative CC-531 colon carcinoma cells10• Using the same in vivo tumour 
models, we describe here the marked SS-R dependent efficacy ofPRRT with [111In_DTPAo]octreotide to 
inhibit the development of SS-R-positive liver metastases. 
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Materials & Methods 
Animals 
Male rats of the inbred WAG and Lewis strain, which were 1 0-14 weeks old and 225-250 g, were 
obtained from Harlan-CPB (Austerlitz, The Netherlands). Animals were kept under standard laboratory 
conditions (12 hours light/12 hours dark) and were given standard laboratory diet (Hope Fanns, Woerden, 
The Netherlands) and water ad libitum. The experimental protocol adhered to the rules laid down by the 
Dutch Animal Experimentation Act and was approved by the Committee on Animal Research of Erasmus 
University. 
Tumours 
The pancreatic tumour, CA-20948, was originally induced by azaserine. The SS-R-positive 
tumour is of acinar origin and is transplantable in syngeneic Lewis rats. The tumour was transplanted and 
maintained in the liver after direct injection into the portal vein. To produce artificial liver metastases, 
tumours were excised from donor livers, cleaned from nonnalliver tissue and pressed through sieves with 
decreasing mess size. The resulting suspension was washed twice in RPMI 1640. Viability was measured 
with trypan-blue exclusion (0.3% in a 0.51% NaCl-solution). A suspension of 2.5x 106 living cells/mL was 
used for direct injection into the portal vein. 
Tumour CC-531 is a SS-R-negative, 1,2 dimethylhydrazine-induced, moderately differentiated 
colon adenocarcinoma, transplantable in syngeneic WAG rats. The tumour is maintained in tissue culture 
as a monolayer in RPMI 1640 medium (GIBCO, Paisly, UK.) supplemented with 5% fetal calf serum. 
The cells were harvested from stationary cultures by gentle trypsinisation. A suspension of2.5x 106 living 
cells/mL was used for direct injection into the portal vein. 
The presence/absence of the SS-R on both tumour cell lines was determined by specific binding 
of C25I_ Tyr3]octreotide. Binding to membrane preparations of CA-20948 pancreatic tumour cells (IC50 of 
0.6 nM and a Bmox 110 fmol per mg membrane protein), but not to the membrane preparations of the CC-
531 colon tumour cells was demonstrated(Van Eijck et al., 1994). 
Radiolabelling and quality control of the radioligand 
[DTPA'joctreotide (Pentetreotide, Dfu'l 4920) and IIlInCI3 (DRN 4901, 370 MBqlrnL in HCI, 
pH 1.5 - 1.9) were obtained from Mallinckrodt Medical (Petten, The Netherlands). Octreotide was a gift 
of Novartis, Preclinical Research (Basel, Switzerland). The labelling was perfonned by diluting the 
freeze-dried [DTPAo]octreotide in 1 mL saline and adding this to the 111InCh. Thirty minutes after the 
start of this procedure quality control was perfonned by instant thin layer chromatography with silica-gel 
and 0.1 M sodium-citrate, pH 5 as eluent, as described earlierl. Labelling efficiency of C Illn_ 
42 
DTPAO]octreotide was over 98 %. Each administration of the radioligand consisted of 370 l\.1Bq IllIn 
labelled with 0.5 fig [DTPAOjoctreotide, referred as 370 MBq (0.5 fig) ["'In-DTPAOjoctreotide. 
Experimental procedure 
Under ether anesthesia the abdomen was opened through a 2.5 cm midline incision. Then 0.5 x 
106 viable, SS-R-positive, CA-20948 cells in 0.2 rnL RPMI 1640 were injected slowly into the portal vein 
through a 0.4 X 12-nun needle. The abdominal wall was closed in one layer by a continuous silk suture. 
The day after the operation the rats were randomised into experimental groups and control groups. Each 
group consisted of 5 or 6 rats. 
In experiment 1, rats in the experimental group were treated with 370 MBq (0.5 ).lg) [Illln_ 
DTPAoJoctreotide iv. on day land 8. Rats in the control group were injected with vehicle, 0.5 ).lg 
[DTPAo]octreotide iv .. In experiment 2 two groups were added in which treatment was given on day 1 or 
8 alone. Experiment 3 was designed to investigate the effect of pretreatment with a SS-R blocking 
concentration of octreotide. The effect of 370 MBq (0.5 ).lg) [I 1 I In-DTPA o]octreotide iv. on day 1 and 8 
was studied with and without SS-R blocking. In the group with receptor blocking rats were treated with 
subcutaneous (sc.) administration of 1 mg octreotide 30 min. prior to injection of the radioligand, as 
described earlier (Breeman et al., 1994). Another 6 rats were injected with 1 mg octreotide sc. only, for 
comparison reasons. In experiment 4 also the importance of the SS-R in PRRT is investigated. In this 
experiment 0.5x 106, SS-R-negative, CC-531 cells in 0.2 mL RPMI were injected into the portal vein. 
Treatment was given according to the same schedule as used in experiment 1. All rats were sacrificed 21 
days after inoculation of tumour cells. Livers were removed, inunersed in phosphate-buffered saline. 
Tumour growth was detennined by two investigators counting the number of metastases on the surface of 
the liver lobes (up to 100), while blinded for treatment modality. 
Statistical analysis 
Statistical analysis was perfonned using Mann-VVhitney U-test on categorised outcomes and 
Fisher's exact test on proportions. Statistical significance was defined as p<0.05. 
Results 
In experiment 1, PRRT with administration of 370 MBg (0.5 ).lg) [llIIn-DTPAo]octreotide on day 
and day 8 induced a significant (p<0.01) decrease in the number of hepatic metastases 21 days after 
direct injection of CA-20948 pancreatic SS-R-positive tumour cells into the portal vein. In the control 
group all animals showed tumour colonies in the liver. After PRRT, tumour colonies were found in only 2 
of6 animals (table 1). Examples oflivers from both experimental and control groups are shown in Figure 
I. 
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Table 1 The effect ofPRRT on SS-R-positive liver metastases. 
Number of metastases 
Treatment o 1-20 21 - 100 >100 
Controls 2 2 2 
PRRT 4 2 
II/umber C?/animals with given range ofmefaslases, 21 days qj1er direct injection oISS-R-positive 
Cl-2094811lmourcells into the portal vein. The ejjixt ofPRRT on days J and 8 ,vith 370 A1Bq (0.5 pg) 
r"1ln-DTPAOjoctreotide is significantly different (p< O.OJ)from the effect qftreatment ,vith 
0.5 JIg "cold" [DTPAOjoctreolide (contro/s). 
Figure 1 The effect ofPRRT on SS-R-positive liver metastases. 
Livers from the control and experimental groups (Iefl and right, re~pectively); data presented in table 1. 
L4i: liver )vith > 100 metastases (controij. Right: Liver ,vith no visible metastases afier PRRT on days 1 
and 8 with 370 lvfBq (0.5 Jig) !,1'ln~DTPAIJoctreolide. 
In table 2 the results are shown of experiment 2 in which two groups were added in which 
treatment was given on day 1 or on day 8 only. Treatment on day 1 and 8 alone also decreased tumour 
load significantly (p<O.OI) while no differences could be found between treatment on either day. 
Treatment on both days however resulted in lesser liver colonies than when a single treatment was 
given (p<D.05). 
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Table 2 The effect ofPRRT on SS-R-positive liver metastases, given at different times. 
Treatment 
Controls 
PRRT day I 
PRRT day 8 
PRRT days I & 8 
Number of metastases 
o 
3 
1-20 
4 
3 
2 
21 - 100 >100 
6 
2 
,"'lumber of animals with given range a/metastases (5 01' 6 animals per groupj, 21 days afier direct injection ofSS-R-
positive CA-20948 tumour cells into the portal vein. PRRT with 370 MBq (0.5 j.1g) /11 fn-DTPAljoctreotide was 
given 011 day I or 8 or on both days I alld 8. The effect of alllreafmcnt schedules was sign!ficanlly different (p< 
O.OI)/i"om the eJlect 0/0,5 /lg "cold" [DTPA1]octreotide on days 1 Gild 8 (Controls). Treatment 011 days 1 and 8 was 
significantly difjerem/j"om treatment 011 day 8 alone (p<0.05). No significant difference was found between the r:;ffect 
of treatment 011 day 8 or day I. 
In the third experiment (table 3) PRRT again induced a significant decrease in the number of 
tumour colonies (p <0.01). Pretreatment with 1 mg octreotide prior to PRRT resulted in a significantly 
higher number of liver tumour colonies compared to PRR T without receptor blocking (p <0.01). In a 
third group that was only treated with octreotide without PRRT all rat livers contained over 100 
colonies. 
Table3 
Treatment 
PRRT 
The effect of pre-blocking of the SS-R with octreotide on PRRT ofSS-R-positive liver 
metastases. 
Number of metastases 
o 1-20 21 - 100 >100 
3 3 
PRRT + block 4 
Octreotide 6 
Number of animals with given range afmetastases, 21 days qfter direct injection q{SS-R-positive CA-20948 tumour 
cells into the portal vein. Effect of PRRT on days I alld 8 with 370 MBq (0.5 Jig) (1Iln-DTPAOjoctreotide without or 
with I mg oetreotide subcutaneously to block the SS-R. A third group of rats were used as control to investigate the 
effect q{ 1 mg octreotide sc .. 
Group 1 vs. group 3: p < 0.01; group I vs. group 2: p < 0.01; group 2 vs. group 3: p < 0.05. 
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The results of PRRT on the fonnation of liver metastases after direct injection of SS-R-
negative CC-531 tumour cells into the portal vein are shown in table 4. No difference in the number of 
liver tumour colonies was found between the experimental group and the control group. 
Table 4 
Treatment 
Controls 
PRRT 
The effect ofPRRT on SS-R-negative liver metastases. 
Number of metastases 
o 1 -20 21 - 100 
3 
2 
>100 
3 
4 
Number oj animals with given range oj metastases, 21 days after direct injection oJSS-R-negative CC-531 tumour 
cells into the portal vein. The efjixt oj PRRT on days 1 and 8 with 370 MBq (0.5 pg) [1l11n-DTPAOjoctreotide is not 
significantly d(fferentfrom the effect oJtreatment with 0.5 Jig "cold" [DTPAOjoctreotide (controls). 
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Discussion 
Several studies have demonstrated that non-radioactive somatostatin analogues inhibit twnour 
growth in experimental tumour models4,22.23. Most twnours used in these experiments contain SS-Rs and 
were studied in vitro and in vivo as a transplantable twnour. Possible mechanisms of the antiproliferative 
effects of these non-radioactive analogues include stimulation of the hepatic reticuloendothelial system 
activity, reduction of portal venous flow and interference with secretion of growth factors such as 
prolactin, growth honnone and insulin-like growth factor-I 2. Results of our previous studies however 
indicated that tumour growth inhibition by octreotide was mediated via SS-R, since no inhibition of 
twnour growth could be fOlmd when SS-R-negative tumour cells were used20. To demonstrate the 
presence of SS-Rs on tumour cells, in vivo peptide receptor scintigraphy with radio labelled somatostatin 
analogues, such as [IIIIn-DTPAo]octreotide has been proven to be a sensitive and specific technique. 
Using this technique, primary tumours and their, often unrecognised, metastases of a wide variety of 
human SS-R-positive tumours can be 10calised9. 
When PRRT with radiolabelled octreotide is considered it is important to know whether 
octreotide has a high affinity for SS-Rs expressed on the twnour cells and whether the radioligand is 
actively internalised by the same cells. Five different SS-R subtypes (SStl_S) have been cloned and 
characterised on twnour cells, which show a distinct phannacological binding profile to octreotide. 
Octreotide was found to bind with high affinity to sst2 and ssts only and showed a low or no affinity to 
sst3, sstl and ss4, respectively. SS-R subtype expression in different types of human cancers has now been 
studied using in situ hybridisation, RNAse protection assays and RT _PCR6,24.25. These results indicate that 
most tumours express multiple SS-R subtypes at the same time. In the vast majority of human SS-R-
positive twnours however sst2 is predominantly expressed. Since several in vivo and in vitro studies 
demonstrated that ellIn-DTPAoJoctreotide retained high affinity to sst2 this compound might be suitable 
for PRRT. The intemalisation by tumour cells of the radioligand is another important aspect of PRRT 
with radio labelled octreotide. Intemalisation by receptor mediated endocytosis may bring the radionuclide 
closer to it is target, the DNA of the tumour cell. Hofland et al. showed that the radioiodinated 
[Tyr3Joctreotide is rapidly internalised by mouse AtT20 pituitary tumour cells and by the primary cultures 
of human GH-secreting pituitary tumour cells25 . Duncan et al. reported internalisation of [lllln_ 
DTPAo]octreotide in vivo into the lysosomes13. In agreement with these studies Andersson et al. recently 
demonstrated internalisation of 1IIIn into hwnan carcinoid m1d gastrinoma cells after incubation with 
[lllln_DTPA o]octreotide26. PRRT with high doses of [I 1 IIn-DTPA o]octreotide might therefore be effective 
because of the emission of Auger- and internal conversion electrons by 1111n11.l2. Due to intemalisation of 
[lllln_DTPA o]octreotide the radiotoxicity of these electrons is high since the DNA of the cell is within the 
micrometer range from the internalised radionuclide. 
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We investigated the antiproliferative effect of CllIn-DTPAo]octreotide on SS-R-positive and -
negative tumour cells in a rat liver metastases model. The major finding from these experiments is that 
PRRT with [' I iIn-DTPA o]octreotide leads to a marked inhibition of intrahepatic growth of SS-R-positive 
hnnour cell colonies. Furthennore, in repeated experiments, most treated animals showed no SS-R-
positive hlmour colonies, an outcome that was not observed in earlier experiments using non-radioactive 
octreotide:w. Possibly the reduced number of tumour colonies could be due to interference with either 
adherence or growth of the tumour cells when therapy was given on day 1, but treatment given eight days 
after tumour cell inoculation also led to a significant tumour growth inhibitory effect. 
The results of the present experiments suggest that tumour growth inhibition was predominantly 
due to the specific binding of C I I In-DTPA o]octreotide to SS-Rs and not to a systemic or a secondary 
mechanism, since PRRT had no effect on SS-R-negative tumour cells. Furthermore, pretreatment with 1 
mg octreotide, resulting in a saturation of the SS-Rs, led to a diminished effect of the PRRT. The finding 
that blocking the SS-R did not completely abolish the therapeutic effect of PRRT may be due to the 
inability to completely block all the receptors by pretreatment, since there is a competitive eguilibrium22.27. 
The presence or abcence of the SS-R is not the only difference between the models; however, no data are 
available on differences in radiosensitivity. 
Jilin, however, is not the optimal radionuc1ide for PRRT, since it lacks the higher energies of u-
and B-particles: the B-particle emitter 90y with a maximum B-energy of 2.3 MeV and a half-life of 64 hr 
may be more suitable. Since gOy -DTPA is not stable in vivo, octreotide has been derivatized with the 
DaTA (tetraazacyclododecanetetraacetic acid) chelator for stable radiolabelling with 90y. This resulted in 
the radioligand: [90Y-DOTAo,D_Phel,Tyr3]octreotide, a single intraperitoneal injection of 500llCi [90y_ 
DOTAo,D-Phel,Tyr3]octreotide led to a significant decrease (25%) in the size of SS-R-positive AR42J 
pancreatic tumours in nude mice ls. Stolz et al. also reported the curative potential of [90Y_DOTAo,D_ 
Phel,T~]octreotide for the SS-R-positive tumour CA-20948 inoculated at the hindlegs in Lewis rats l9• 
The presence of sst2 and sst5 was reported for this model in this study. 
Clinical phase I studies with this radioligand in patients with neuroendocrine tumours have already 
started. A third experimental study similarly demonstrated an effect on tumour growth by radiolabelled 
analogues in animal models. Multiple intratumour injections of lS8Re-Iabelled RC-160, another 
somatostatin analogue, resulted in a reduction of tumour size and prolonged survival in nude mice bearing 
positive PC-3 human prostatic adenocarcinomas 17. PRRT of SS-R-positive tumours with [lllIn_ 
DTPA o]octreotide has also been carried out in several patients with inoperable, metastasised neuroendo-
crine tumours. After multipJe high doses of radioactivity of C llln-DTPAo]octreotide (up to 53 OBq) 
impressive effects on honnone production and a decrease in tumour volume have been observed14.1S . 
Typical radiation doses to tissues with administered doses of 6000-7000 MBg [I I I In-DTPA o]octreotide 
are: kidneys 300-1400 cOy (depending on the relative biological effectiveness (RBE, 1-20) for Auger 
electrons), spleen 20 cOy, liver 50 cOy, bone marrow 13 cOy, thyroid gland 25 cGy, and pituitary 70 
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cGy2S. In addition, within these administrated doses of 6000-7000 MBq the estimated/calculated tumour 
radiation dose are for a lO-g tumour (assumptions: 1% uptake; effective half-life equal to the physical 
half-life) 1700 and 6700 cGy (RBE for Auger electrons 1 and 20, respectively) and for a 100-g tumour (1 
% uptake) 250 and 750 cGy, respectiveli9. We are cillTently also performing toxicology studies after 370 
MBq (0.5 J..Lg) [IIIIn-DTPAoJoctreotide in control rats not bearing tumourS. Since we do realise that 
tumour load in our experiments was relatively small and the doses used relatively high, more PRRT 
experiments, in more advanced stages of tumour development and with different doses of [IIIIn_ 
DTP A o]octreotide, are necessary. However, our present results suggest that PRR T may be a promising 
new treatment modality for patients with inoperable, locally advanced or disseminated SS-R-positive 
tumours. The results of these experimental methods suggest that the antiproliferative effect is due to 
selective binding to the SS-R and not to a systemic or secondary mechanism. 
Therefore we conclude that: (1) high radioactive doses with e11In-DTPAo]octreotide for PRRT 
can inhibit the growth ofSS-R-positive liver metastases in an animal model, (2) PRRT is only effective if 
SS-R are present on the tumours, and is therefore receptor mediated and (3) the effect of PRRT \\lith 
e11In-DTPAo]octreotide can be reduced by pre-treatment with "cold" octreotide, which indicates that 
receptor binding is essentail for PRRT. 
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CHAPTER 5 
PEPTIDE RECEPTOR RADIONUCLIDE THERAPY 
WITH RADIOLABELLED OCTREOTIDE; 
TIMING AND DOSAGE 
Adapted from: 
The Quarterly Jounal of Nuclear Medicine 1999; 43: 356-366 
G.D. Slooter, S WA. Nij Bijvank, WA.P. Breeman, A. G.J. Aalbers 
RL Marquet, E.P. Krenning and c.H.J van EiJck 
Abstract 
Most neuroendocrine tumours and several other tumours such as breast carcinoma and malignant 
lymphoma express somatostatin receptors (SS-Rs). Lesions expressing these receptors can be visualised in 
vivo by receptor scintigraphy using low radioactive doses of the radiolabelled somatostatin analogue 
C11ln-DTPAo]actreotide. The same agent given in a high radioactive dose can be used for Peptide 
Receptor Radionuclide Therapy (PRRT). The aim of this Shtdy was to investigate the effect of different 
radioactive doses and different treatment schedules for PRR T with [Ill In-DTP A °Joctreotide. 
SS-R-positive CA-20948 tumour cells were injected into the portal vein on day 0 to form tumour 
colonies in the liver. Tumour gwwth was evaluated 21 days later. In the first experiment PRRT was 
perfonned with 3.7, 37 or 370 MEg ellln-DTPAo]octreotide on day 1. In further experiments PRRT was 
perfonned with 370 MEg on day 1 and/or 8, day 6 or 12 and on day 7 or 14 respectively. 
PRRT with 370 MEg C11ln-DTPAo]octreotide significantly reduced tumour growth compared to 
controls ( p<O.Ol) and was superior to doses of 3.7 and 37 MEg (p<0.05). Other experiments were 
continued with 370 MEg which was an effective dose on days 1 through 12. PRRT given twice on day I 
and 8 was more effective than single dose on day 1 or 8. There was no evidence of severe toxicity. 
PRRT with high doses ofC11ln-DTPAoJoctreotide is effective in SS-R-positive tumours. Also 
established tumours in the liver could effectively be treated and there was no severe toxicity. 
Therefore PRRT could be a promising treatment modality for patients with inoperable SS-R-positive 
tumours. 
S4 
Introduction 
Somatostatin is a small regulatory peptide which inhibits the release of various hormones and 
may act as neurotransmitter in the central nervous system L2. The tetradecapeptide somatostatin itself is 
unsuitable for treatment, because of its very short half-life of approximately 3 minutes in man after 
intravenous injection. The somatostatin analogue octreotide has a half-life of 30 - 60 minutes and a more 
potent action than somatostatin. Octreotide has clinically been used widely in controlling symptomatology 
of excess hormone production of gastroenteropancreatic (GEP) tumours like carcinoid tumours, VIPoma, 
glucagonoma, insulinoma, and gastrinoma3.). Several experimental and clinical studies also suggest an 
antiproliferative effect of somatostatin and its analogues6. 12. Critical to these actions is the presence of 
somatostatin receptors (SS-R), which like other membrane receptors subserve two functions: (1) to 
recognise the ligand and bind it with high affinity and specificity, and (2) to generate a transmembrane 
signal that evokes a biological response. At least five different human SS-R subtypes (sst l.)) have been 
clonedl3. All subtypes bind somatostatin with high affinity, while their affinity for the somatostatin 
analogue, octreotide, differs considerably. Octreotide binds with high affinity to sst2 and sst5. to a lesser 
degree to sst3. while no binding to sstl and ss4 occurs. SS-R's have been demonstrated on a variety of 
human tumours and their metastases!4. The vast majority of human SS-R-positive tumours express sst2 15• 
For the visualisation ofSS-R-positive tumours in vivo somatostatin receptor scintigraphy with the 
radioactive somatostatin analogue [' [[Indium-diethylenetriaminopenta-acetic acid C I lln_ 
DTPAo)}octreotide (Octreoscan®) (Cllln-DTPAo]octreotide) is used and this technique has become an 
important diagnostic tool in the management of patients with SS-R-positive tumours I6- 19 • [llln emits not 
only gamma rays, which can be visualised, but also internal conversion- and Auger electrons with a 
medium to short tissue penetration 20-22. With the active process of internalisation the radionuclide is 
brought close to its possible target, the DNA of the tumour cell. Therefore, an effect on tumour cell 
proliferation is to be expected. We previously reported the antiproliferative effect of Peptide Receptor 
Radionuclide Therapy (PRRT) with 370 MEq C11ln-DTPAo]octreotide on the growth of SS-R-positive 
CA-20948 pancreatic twnour cells in the rat liver. We demonstrated that this effect of PRRT is SS-R 
dependent since pre-blocking the receptors with a high dose of non-radioactive octreotide almost 
completely cancelled out the effect. Moreover, no effect was achieved with SS-R-negative CC531 colon 
carcinoma cells23 . 
In the present study we investigated the effect of different treatment schedules of PRRT with 
[IIIIn-DTPAo]octreotide in a liver metastases model in the rat. Therapy was given with different doses 
ranging from 3.7 MEq to 370 I'v1l3q to investigate the optimal treatment dose and with different time 
intervals up to 14 days after tumour cell injection into the portal vein to detennine whether PRRT with 
Cilln-DTPAo]octreotide is also effective on more established tumours. To investigate short tenn toxicity 
kidney and liver tissue were histologically examined and biochemical parameters were monitored. 
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Materials & Methods 
Animals 
Male rats of the inbred Lewis strain, which were 10-14 weeks old and 225-250 g, were obtained 
from Harlan-CPB (Austerlitz, The Netherlands). The animals were kept under standard laboratory 
conditions (12 hours lighU12 hours dark) and were given standard laboratory diet (Hope Fanns, Woerden, 
The Netherlands) and water ad libitum. The experimental protocol adhered to the rules laid down by the 
Dutch Animal Experimentation Act and was approved by the Committee of the Erasmus Medical Centre. 
Tumour 
The pancreatic tumour, CA-20948, was originally induced by azaserine24• The SS-R-positive 
tumour is of acinar origin and is transplantable in syngeneic Lewis rats. The tumour was transplanted and 
maintained in the liver after direct injection into the portal vein. To produce artificial liver metastases, 
tumours were excised from donor livers, cleaned from nonnalliver tissue and pressed through sieves with 
decreasing mess size. The resulting suspension was washed twice in RPMI 1640. Viability was measured 
with trypan-blue exclusion (0.3% in a 0.9% NaCI-solution). A suspension of 2.5x 106 cells/mL was used 
for direct injection into the portal vein. 
The presence of the SS-R was demonstrated by specific binding of e25I-Ty?]octreotide to membrane 
preparations of CA-20948 pancreatic tumour cells: ICso of 0.6 nM and a Bmax 110 fmol per mg membrane 
protein l2 . 
Labelled pep tides 
[DTPAOjoctreotide (Pentetreotide, DRN 4920) and '''InCb (DRN 4901, 370 MBqlmL in HC1, 
pH 1.5 - 1.9) were obtained from Mallinckrodt Medical (Petten, The Netherlands). (DTPAo]octreotide 
was labelled with t t lInCh as described previously25 26. 
Experimental procedure 
On day 0 in each experiment, the abdomen was opened through a 2.5 cm midline incision under 
ether anaesthesia. Then 0.5 x 106 viable, SS-R-positive, CA-20948 cells in 0.2 mL RPMI 1640 were 
injected slowly into the portal vein through a 0.4 X 12-mrn needle. The abdominal wall was closed in one 
layer by a continuous silk suture. The day after the operation the rats were randomised into experimental 
groups and control groups. Each group consisted of 5 to 8 rats. 
The fITSt experiment was designed to detennine the minimal effective dose ofPRRT. Groups of 8 
animals were injected with 3.7 or 37 or 370 MBq (O.5J.1g) C11In-DTPAoJoctreotide intravenously on day l. 
In further experiments PRRT was given with 370 MBq on day 1 and/or 8, 6 and 12 and 7 and l4 
respectively. All rats were sacrificed 21 days after inoculation of tumour cells. The livers were removed, 
56 
inunersed in phosphate-buffered saline and then dried and weighed. Tumour growth was determined by 
two investigators counting and ranking the number of metastases on the surface of the liver lobes, while 
blinded for treatment modality. The kidneys were removed for histological examination. 
Statistical analysis 
Statistical analysis was performed using Mann-Whitney U-test on categorised outcomes and 
Fisher's exact test on proportions. Statistical significance was defined as p< 0.05. 
Results 
Dose-effect relation 
The results of PRRT with different radiation doses of [II 1 In-DTPA °Joctreotide on the growth 
of tumours in the liver are given in table 1. PRRT with 370 MBq dose reduced the number of tumour 
colonies and wet liver weight compared to control animals (p<0.05). PRRT with 370 MBq dosage had 
more effect on the tumour score and wet liver weight than the 37 MBq and 3.7 MBq doses. 
Table 1 Dose effect relation of PRRT with C [IIn-DTPA °Joctreotide on the tumour score 
of SS-R-positive liver colonies in the rat. 
Radiation dose 
3.7 MBg (n~8) 
37 MBg (n~8) 
370 MBq(n~8) 
Controls (n~4) 
Liver weight (g) 
Mean (s.e.m.) 
16.4 (3.7) 
17.9 (5.0) 
14.1 (5.8)' 
17.4 (6.0) 
Tumour score 
o 1+ 2+ 3+ 
2 
4 4 
versus tumour score 
4+ 
5 
4 
5+ 
4 
4 
weight and number oj animals }vith given range oj tumour score, 21 days after direct injection oj S5 -R-
positive CA-20948 tumour cells into the portal vein. PRRT with 3.7 MBq. 37 MBq or 370 MBq [111[11-
DTPAf)joctreotide was given on day /. PRRT l;vith 370 MBq induced a sigl1!ficont reduction Qf tumour growth 
compared to control and other radiation doses. 
Effects oj PRRT with!' II In-DTPAOj oelreatide 
Since only a significant decrease in tumour growth was found with PRRT with a dose of 370 
MBq we continued our experiments with this dose. In table 2 the results of treatment on day 1 or 8 and 
on days 1 and 8 are expressed compared to controls. PRRT on day 1 or 8 decreased the number of 
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tumour colonies and the wet liver weight (p<O.05) compared to controls, while no difference could be 
found between treatment on either day. 
Table 2 The effect ofPRRT with 370 MBq [llIIn-DTPAo]octreotide in different treatment 
schedules on the tumour score of SS-R-positive liver colonies in the rat. 
Liver weight (g) Tumour score 
Treatment Mean (s.e.m.) 0 1+ 2+ 
PRRT day 1 (n~5) 13.0 (5.6) 2 
PRRT day 8 (n~5) 10.8 (!.l) 
PRRT day 1 & 8 (n~5) 12.3 (3.3)** 3 2 
Controls (n~6) 21.6 (1.7)* 
* p<O.05 versus all PRRT groups; based on tumour score and liver weight 
** p<O.05 versus control, PRRT day 1, PRRT day 8; based on tumour score 
3 
3+ 4+ 5+ 
2 
2 
6 
Liver weight and number of animals with given range a/tumour score, 21 days after direct injection 0/ SS-R-
positive CA-20948 tumour' cells into the portal vein. PRRT with 370 MEq (0.5f1g) /Jlfn-DTPA()joctreotide was 
given on day 1 or 8 or on both days. PRRT on day 1 and 8 induced a significant reduction a/tumour growth 
compared to control treatment. Treatment on both days was superior to treatment on either day. 
Treatment on both days, however, resulted in a further decrease compared to single treatment 
(p<0.05). The results of the experiment with PRRT on days 6 or 12 are summarised in table 3. PRRT 
on day 6 or 12 decreased both the number of tumour colonies and wet liver weight compared to 
controls. In the experiment with PRRT on day 7 and 14 the antiproliferative effect was significant 
(p<0.05) based on liver weight and tumour score when PRRT was given on day 7 but not significant 
when given on day 14 (data not shown). 
Table3 The effect ofPRRT with 370 MBq [I 1 I In-DTPAoJoctreotide in different treatment 
schedules on the tumour score of SS-R-positive liver colonies in the rat. 
Liver weight (g) Tumour score 
Treatment Mean (s.e.m.) 0 1+ 2+ 3+ 4+ 5+ 
PRRT day 6 (n~8) 11.5 (1.3) 3 5 
PRRT day 12 (n~8) 9.5 (1.7) 3 4 
Controls (F8) 16.8 (3.3)* 8 
* p<O.05 versus PRRT on day 6 and day f2; based on tumour score and liver weight 
Liver weight and number 0/ animals with given range a/tumour score. 2f days after direct injection o/SS-R-
positive CA-20948 tumour cells into the portal vein. PRRT with 370 MEq (O,5f1g) /llfn-DTPAOjoctreotide was 
given in on day 6 or f2. PRRT on day 6 and J 2 induced a significant reduction 0/ tumour growth compared to 
controls that were injected with saline. 
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Discussion 
Most carcinoid tumours and endocrine pancreatic tumours, with the exception of insulinomas, 
have a malignant potential and have already metastasised at the time of diagnosisl 8. These tumours are 
generally slow growing and most of the clinical distress is related to the hypersecretion of honnones, 
which often incapacitates the patient and causes long and repeated hospital stay. Since the majority of 
the patients have both intrahepatic and extrahepatic dissemination curative resection of the liver is only 
possible for a selective group though also cytoreductive hepatic surgery leads to sustained palliation of 
symptoms, reduces the need for additional treatment and prolongs survival in selected groups ofpatients27• 
31. Because a limited number of patients can be cured by surgery there is a need for systemic therapy. The 
clinical use of the somatostatin analogue octreotide in this type of patients is of considerable help in 
controlling symptomatology. Debilitating diarrhoea, dehydration and hypokalemia (VIPoma), peptic 
ulceration (gastrinoma), life-threatening attacks of hypoglycemia (insulinoma) and necrolytic skin 
lesions (glucagonoma) can be well controlled during chronic treatment with octreotide3•s. The 
observation that somatostatin inhibits the release of various peptide honnones has stimulated the 
interest in its use as an anti proliferative agent. In pre-clinical studies somatostatin analogues inhibit the 
growth of a wide variety of SS-R-positive as well as SS-R-negative tumours in vivo and in vitro7,9,32. 
We demonstrated earlier in the same tumour model as in the present paper that tumour growth of SS-
R-positive tumour cells was decreased by non-radioactive octreotide while no effect was found for SS-
R-negative tumour cells suggesting that the antiproliferative effect of octreotide is SS-R dependent12. 
To demonstrate the presence of SS~R on tumour cells in vivo somatostatin receptor scintigraphy 
(SRS) with CllIn-DTPAo]octreotide has been proven to be a sensitive and specific technique. Using this 
technique, primary tumours and their, often unrecognised, metastases of a wide variety of human SS-R-
positive tumours can be locatised I6•19 . After systemic injection of Cllln-DTPAo]octreotide the 
radionuc1ide is internalised and transported into the lysosomes by SS-R specific and temperature 
dependent process starting with endocytosis33J 4. The metabolite It I In-DTPA-D-Phe is not capable of 
passing the lysosomal membrane resulting in a biological half-life of in human tumour tissue of> 700 
homs l7.35. IllIn not only emits gamma-rays, which can be visualised during scintigraphy, but also internal 
conversion~ and Auger electrons having a medium to short tissue penetration (200~550 ).1m, 0.02-10 11m, 
respectively). Therefore, an effect on tumour cell proliferation could be expected, as the radiotoxicity of 
the radionuclide is very high if the DNA of the cell is within the particle range20,21. ['llln_ 
DTPA °Joctreotide has an appropriate distribution profile in humans to perfonn SRS with low doses of 
radioactivity and PRRT with high doses of radioactivity36,37. In previous studies in our model with liver 
metastases we found that PRRT with 370 MBq CIIIIn-DTPAo]octreotide decreased the growth ofSS-R~ 
positive CA-20948 tumours. The necessity of the SS-R was proven since blocking the SS-Rs by pre~ 
treatment with octreotide annihilated the effect ofPRRT. Moreover no effect was found on SS~R~negative 
cells. 
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In the present study we demonstrated a dose-effect relation for PRRT with CI1In-
DTPAo]octreotide. The 370 MBq dose had more effect on tumour growth than 37 MBq or 3.7 MBq. 
The dose of 37 MBq in our rat experiments equals the dose used in humans in dose/kg which is 110-
160 MBq/kg. Since PRRT with 370MBq was demonstrated to be superior to lower doses we continued 
our experiments with 370 MBq. In the experiments with different treatment schedules of PRRT with 
[lllln-DTPAo]octreotide we confirmed that tumour growth can be inhibited with PRRT, even with a 
single dose 12 days after inoculation of the tumour cells. These findings suggest that even on 
established tumours reduction of tumour volume can be obtained and thereby support the results of 
case reports that describe reduction of tumour volume36. 
For clinical radiotherapeutic use the toxicity ofPRRT on nonnal tissues should be considered. 
Side effects of PRRT are to be expected in organs consisting of tissues that express SS-Rs, such as 
adrenals and pituitary gland. Also kidney function could be influenced by PRRT since eilln-
DTPAo]octreotide is cleared mostly excreted through the urinary system and binds selectively to the 
excreting tubuli which is demonstrated clinically by high uptake in normal kidney tissue. Histological 
examination of kidneys in our experiments with [llIIn-DTPAo]octreotide showed no alterations 
compared to kidneys of untreated animals. Glomemlar filtration rates of creatinine and urea were not 
influenced by PRRT with 370 MBq (data not shown). To investigate the possible side effects our group 
has perfonned toxicity studies with PRRT with 370 MBq in non tumour-bearing rats. Preliminary results 
from this study with a follow up to 6 months post PRRT were that no alterations were found in 
hematological - and endocrinological factors; including white - and red blood cell count, platelet count 
and the serum level of thyroid stimulating hormone, follicle stimulating hormone, glyco-haemoglobin, 
alanine transaminase and aspartate transaminase. Also renal excretion profiles were not influenced 
(manuscript in preparation). 
It has been demonstrated that the distrubution of SS-Rs is not homogeneous throughout 
established solid tumours. It is to be expected that heterogeneity of SS-R expression in large tumours 
will cause incomplete responses during PRRT with the radionuclide 111In because of the short particle 
range of its Auger- and conversion-electrons. For radiotherapeutic applications, also other radionuclides 
like Yttrium-90 ~oY) have been proposed for coupling to somatostatin analogues. goy, with a half-life 
time of 2.7 days, is a pure ~-emitter, with a tissue range up to 1 cm. The electrons have a maximum 
energy of 2.3 Mev. goy shows dissociation from DTPA-conjugated peptides in serum, resulting in 
hematopoietic toxicity in vivo, therefore, Ty2 -octreotide, which has a higher binding affinity for sst2 than 
octreotide itself, has been derivatised with the chelator DOT A (tetracyclododecanetetraacetic acid) 
enabling stable radiolabelling with both gOy and 111In. Preclinical studies and clinical studies with 
[DOTAo,Ty2}octreotide showed favourable biodistribution and tumour uptake characteristics2s.3s. In our 
model we also performed an experiment with PRRT with [90Y-DOTAO,Ty~Joctreotide. PRRT with 93 
MBq rOY-DOTAO,Tyr]octreotide on day 1 resulted in a decrease (p<0.05) in tumour growth 
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compared to animals injected with saline (controls) and compared to animals injected with 2.5 I-lg non 
radioactive [DOTAO,Tyr3]octreotide (vehicle). There was no difference between control and vehicle 
groups. The non~radioactive vehicle [DOTAO,Ty~Joctreotide did not influence tumour growth 
compared to controls, indicating that the tumour growth inhibition of PRRT is due to the radionuclide 
90y Theoretically the ~-particles of 90y might have additional beneficial characteristics, due to the 
effect of "cross-fire". Tumour cells lacking the SS-R might be hit by an electron coming from a 
neighbouring SS-R-positive cell, which has internalised the radioligand. This may lead to a high and 
more homogeneous radiation dose in larger parts of the tumour. Further experiments with PRRT with 
IllIn and 90y labelled somatostatin analogues on more established tumours should reveal these 
beneficial effects. 
Three other experimental studies with radiolabelled somatostatin analogues demonstrated the 
antiproliferative potential of PRRT on solid subcutaneously transplanted tumours, using [MCU_ 
TET A o]octreotide, COy -DOT A 0, Tyr3]octreotide and 188Re_RC_160, respectively39.41. In these 
experiments therapy was given by intratumour or intraperitoneal injection, resulting in a significant 
decrease in tumour size. We also demonstrated tumour growth inhibition of subcutaneous SS-R-
positive tumours as has been published previousll2• In these experiments PRRT was given 
intravenously. In addition, PRRT with high radioactive doses of C11In-DTPAo]octreotide or [90y_ 
DOTAO,Tyr3]octreotide has been initiated clinically 37.43-46. 
New developments in molecular biology have made it possible to transfect SS-R-negative 
tumour cells with a SS-R-gene. The group of Susini has developed an approach using sstz-gene 
transfer for the treatment of pancreatic cancer47 . By inducing the SS-R on SS-R-negative tumours, 
treatment with PRRT might be possible. Moreover, transfection of SS-R-positive tumours with a SS-
R-gene can increase the homogeneity of distribution of tumour cells expressing the SS-R and thereby 
increase the efficacy of PRRT. We are currently investigating this strategy of treatment of cancer with 
SS-R-negative colon adenocarcinoma cells CC531 in our model. 
Peptide receptor radionuclide therapy (PRR T) with intravenously administered radiolabelled 
somatostatin analogues is effective in our liver metastases model in the rat. In our experimental model 
there were no signs of acute toxicity. Further investigations will focus on treatment of SS-R-negative 
tumours and treatment with other radionuclides. Our preclinical studies will help to optimise PRRT 
clinically. 
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CHAPTER 6 
LIVER REGENERATION AND TUMOUR GROWTH: 
AN INTRODUCTION 
Introduction 
Surgical excision of liver tumours represents the only curative treatment for primary and 
metastatic liver malignancies. This operation in which the tumours in the liver are excised together with 
surrounding nonnalliver tissue is called partial hepatectomy (PHx). For colorectal tumours the results of 
PHx compare favourably with the nanrral outcome for selected groups of patients l . However, despite the 
curative potential of PH x, recurrence has been reported in 65-80 % of the patients2• The predominant site 
of recurrence is within the liver remnant and the majority of recurrence is diagnosed within the first year 
after the operationl.3-6. The high number of early recurrences suggests that PHx might act as a 'double-
edged sword'. On one hand survival after PHx is increased but on the other hand resection might provoke 
enhanced tumour growth. 
Several groups have fOlmd experimental evidence for stimulation of tumour growth by PHx in 
various animal models (table 1); both intrahepatic and extrahepatic lesions were fOlmd to grow more 
quickly after the operation7•27. Clinical support for this theory was published recently. Elias et al.28 
demonstrated that during liver regeneration following right portal embolisation the growth rate of liver 
metastases in the left liver lobes was increased and even more rapid than the growth of liver parenchyma. 
These findings are in agreement with studies in rats which demonstrate accelerated tumour growth in 
regenerating liver lobes and inhibited tumour growth in atrophied liver segments after selective portal 
embolisation29• Various explanations for this phenomenon have been described. Growth factors, like 
hepatocyte growth factor (HOF), transfonning growth factor-alpha (TGFu), epidennal growth factor 
(EGF) and other growth regulators, produced by the regenerating liver, that orchestrate the process of 
liver regeneration, have also been implicated as tumour growth promoting agents 30. Other possible 
mechanisms include: the detrimental effect of surgical manipulation3l , the generalised 
immunosuppression provoked by PHx I3.32 , and impaired Kupffer cell function33-35 • 
If this phenomenon of increased tumour growth after PHx can clinically be substantiated early 
systemic chemotherapy after PHx could be of great benefit 36-38. However, this adjuvant treatment 
should not interfere with liver regeneration39since it is the unique capacity of the liver to regenerate 
that enables the patient to recover from extensive liver loss. 
Liver regeneration 
The ancient Greeks recognised liver regeneration in the myth of Prometheus. Having stolen 
the secret of fire from the gods of Olympus, Prometheus was condemned to having a portion of his 
liver eaten daily by an eagle. His liver regenerated overnight, thus providing the eagle with eternal 
food and Prometheus with eternal torture40. In those days they must have known that the mammalian 
liver has the unique ability to restore its volume after tissue loss. In present times we are able to 
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quantify liver regeneration since there are techniques available, like computerised tomography and 
magnitic resonance imaging, Restoration of liver volume in human is complete within one month. In a 
group of patients that underwent right hepatectomy in a living donor liver transplantation program the 
mean residual1iver mass was 600 g. The average liver volume was doubled in 7 days and the remnant 
liver reached its maximum volume after 30 days41, However, in adults, after PHx the liver does not 
always regain its pre-operative size42. 
If, in the rat, two thirds of the liver volume is removed the residual liver tissue induces 
compensatory hyperplasia to regain the original volume within 10 days. The magnitude of this 
regeneration process is proportional to the volume removed or damaged43 . The core reference for 
experimental studies on liver regeneration in the rat is the work of Higgins and Anderson, published in 
193144 , They described a simple technique to resect 70% of the liver volume by ligating and dissecting 
the left lateral and median liver lobes at their vascular pedicle (70% PHx). Regeneration after PHx is a 
precise, well orchestrated process involving a complex scheme of stimulatory and inhibitory effects 
on cell growth. The role of polypeptide growth factors has been investigated most. The numerous 
growth regulators that are involved in hepatic regeneration are listed in table I 45 , Liver regeneration 
after PHx is carried out by proliferation of all the existing mature cellular populations composing the 
intact organ. These include hepatocytes, biliary epthelial cells, fenestrated endothelial cells, Kupffer 
cells and hepatic stellate cells. Hepatocytes, are the first to proliferate and most of the hepatocytes 
participate; 95% in young - and 75% in very old rats46, 24 hours after PHx there is a peak in DNA 
synthesis followed by a smaller peak between 36 and 48 hours. The first peak of DNA synthesis of the 
other cells of the liver is after 48 hours4o, The tissue and serum levels of most growth regulating 
substances show a peak within a few hours after PHx and have become nonnal within 48 hours. Since 
the first 48 hours of liver regeneration are so outspoken the putative effect of regeneration on tumour 
growth is expected to occur most within these 48 hours, 
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Table 1 Hepatic growth regulators. 
Polypeptide Growth Factors: Hepatocyte growth factor 
Epidermal growth factor 
Transforming growth factor a 
Honnones and Nutritients: 
Growth Inhibitory Factors: 
Insulin-like growth factors and growth hormone 
Tumour necrosis factor a 
Augmenter of liver regeneration 
Heparin-binding growth factors 
Fibroblast growth factors 
Hepatic stimulatory substance 
Hepatopoietins 
Keratinocyte growth factor 
Miscellaneous hepatotrophic factors 
Adrenal cortical honnones 
Catecholamines 
Estrogens and androgens 
Insulin and glucagon 
Nutrients 
Parathyroid honnone, calcium, vitamin D 
Prolactin 
Prostaglandins 
Thyroid hormones 
Vasopressin 
Transfonning growth factor ~ 
Hepatocyte proliferation inhibitor 
Interleukin 1 ~ 
Other growth inhibitors 
Source: Kren et al. 1997, Ann N Y Acad Sci 
An interesting phenomenon is the existence of stem cells. Ductular oval cells i11 the liver have 
the possibility of differentiation i11to hepatocytes under appropriate experimental conditions47 . Also it 
has been shown in animal models that hepatocytes and ductal cells can derive from bone marrow 
cells4s. In patients that had undergone bone marrow transplantations, popUlations of hepatocytes of 
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donor origin were found in the livers at autopsy49. In non-regenerative conditions liver repopulation 
occurs when transplanted cells have a growth advantage over damaged recipient liver cellsso . 
Significant contribution of the stem cells to the regeneration process only occurs under circumstances 
in which the residual differentiated cells are functionally compromised andlor cannot proliferatesi . 
Origin of recurrent liver metastastases 
There are different theories about the origin of new metastases in the liver that give rise to 
recurrences. Tumour cells can spread from a remnant of the primary tumour or from extra hepatic 
secondaries to form de novo metastases in the liver. Also tumour cells that are spread during PHx can 
settle again in the liver5253 • But most likely (micro)metastases in the liver that had not been detected by 
pre-operative imaging and remained undetected at laparotomy (occult metastases) grow out to fonn 
detectable metastases54.55 . It has been suggested that most of the occult metastases are non-proliferating 
single tumour cells that are spread throughout the liver l6. These "dormant" tumour cells could be triggered 
to start proliferating by changes in extracellular host factors. Clinical studies of tumour reClUTence in 
melanoma show that single tumour cells or small groups of tumour cells can lllldergo a period of 
dormancy followed by rapid growth during reJapse56• This could be explained by a balance between 
proliferation and apoptosis of tumour cells57 or by the lack of vascularisation of the tumour which is 
necessary to enlarge to a size beyond a few mm58. Liver regeneration after partial resection could provide 
such a trigger for metastatic growth and act as an alarm clock, awaking the dorn1ant tumours. 
Mechanisms of increased tumourgrowth after partial hepatecomy 
Hepatocyte growth factor 
Hepatocyte Growth Factor (HGF) also known as Scatter Factor has been identified in 1984 by 
Nakamura et al.s<) as a specific factor to trigger liver regeneration. HGF is produced in many cell types in 
the liver including Kupffer cells, endothelial cells, fibroblasts and fat stOling cells60 . Following PHx there 
is a marked increase in the level of circulating HGF and increased expression ofHGF mRNA in liver cells 
but also in cells of other organs, e.g. the kidney61,62. Infusion of HGF is known to accelerate liver 
regeneration. HGF may be important in the growth and development of cancer metastases by several 
mechanisms. Over-expression of HGF receptors on the tumour cells might increase motility and alter the 
invasive nature of malignant cells60. Recombinant human HGF ,injected directly into the tumours, 
increased proliferation of the established tumours of three hepatoblastoma cell lines63 . There is also 
evidence of paracrine and autocrine regulation by HGF60.64.65. HGF may also stimulate primary and 
secondary tumour growth by stimulation of angiogenesis66•67• 
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Transforming Growth Factor and Epitelial Growth Factor 
De Jong and Lont et al. describe extensively the putative role of transforming growth factor 
(TGF-a) and epithelial growth factor (EGF)18. Both the level ofTGF-a and EGF are increased during 
liver regeneration68,69.These growth factors stimulate hepatocyte growth in vivo and in vitro. 
Expression of EGF receptor and production of TGF-a that can result in autocrine and paracrine 
stimulation was found in various colorectal cancersl8. The role ofTGF-J3 is more complex. It appears 
to be the main negative growth regulator peptide of the regenerating process 70. Picardo et al. found 
that TGF-a and TGF-J3 levels within the regenerating liver in the rat are increased23 . In vitro 
experiments with Morris hepatoma cells showed a growth stimulation with TGF-a but a growth 
inhibition of TGF-J3. TGF-J3, however, in other experiments has shown to be a promotor of tumour 
growth71.72. TGF-J3 might therefore be a bifunctional regulator of cellular growth73,74 of which its 
impact on tumour growth in conditions of regeneretion is yet to be elucidated. 
Other growth factors 
Insulin-like growth factor-l and -2, (IGF) production by the liver during regeneration is not 
increased. There is evidence to suggest, however that lGF may playa role in regulation of liver growth 
as autocrine factors since IGF-I receptors are expressed in regenerating rat liver and not in non-
proliferating cells from rat and human livers45 . Basic fibroblast growth factor (bFGF) plays a role in 
angiogenesis and influences tumour growth by promoting vascularisation. Also a direct stimulating 
effect on various colon carcinoma cell Jines has been demonstrated75 . 
Surgical trauma 
The relationship between tumour growth and wound or tissue healing is an area that has 
particular relevance to all surgeons with an interest in cancer management. In a series of experiments 
with over 800 rats Fisher and Fischer in 1959 found that repeated laparotomy increased the incidence 
of metastases to the liver from 24% to 47 %. If manipuaiation of the liver was added to the repeated 
laparotomy the incidence was as high as 84%31. The impact of surgical trauma might be limited in the 
experiments listed in table 2, which all use the procedure described by Higgins and Anderson in 1931. 
In this procedure there is only limited manipulation of the remnant liver. The liver consists of 7 lobes, 
each with separate vascularisation and biliary ducts. During PHx the entire left-lateral and median 
lobes are removed by ligating their vascular pedicles. The lobes of the remnant liver are left intact and 
do not have wound surfaces. Furthermore, the experiments on liver regeneration and tumour growth 
were carried out with sham operated control animals with equivalent manipulation to the liver. 
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Table 2 Effects of partial hepatectomy on the growth of tumour within the liver or 
at extra hepatic locations in rats and mice. 
Reference Method Tumour growth within 
liver 
Paschkis7 1955 70% PHx 
Fishers 1959 70% PHx t 
Gershbein9 1963 70% PHx t 
Ichihashi 10 1984 70% PHx t solid 
Ramantanis ll 1985 sera or spleen cells 
of 70% PHx rats iv. 
Van Dale '2 1988 70% PHx t i.po. 
Panis l3 1990 70% PHx = l.po. 
Loizidou l4 1991 70% PHx t i.po. 
Asaga 15 1991 70%+ 35% PHx 
Panis 16 1992 70% PHx t i.po. 
Mizutani 17 1992 70% PHx t Lpo. 
De Jong lS 1995 70% PHx t solid 
Karpoff i9 1996 70% PHx t 
Loizidou20 1996 Fibroblasts 
of 70% PHx rats 
Schindee1 1997 70% PHx t solid 
Ikeda" 1997 70% PHx 
Picardo23 1998 70%+ 30% PHx t i.po. 
00024 1986 70% Phx 
Leith25 1992 70% PHx 
Morimoto26 1992 40% PHx t 
Gutman27 1994 70% PHx 
(1) increased tumour growth, rJ) inhibition a/tumour growth, 
(=) no change in tumour growth, (-) not investigated 
(solid) outgrowth Qj'solid tumour implanted in the remnanlliver 
Extra hepatic tumour 
gwwth 
t subcutaneous 
= subcutaneous 
t subcutaneous 
t bulbus vestibuli 
t 
= retroperetoneai 
= renal subcapsular 
t subcutaneous 
t subcutaneous 
tlung 
= lung 
.J, subcutaneous 
t subcutaneous 
tlung 
t subcutaneous 
(Lpo.) tumour growth within the liver after injection of tumour into the portal vein 
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Immunosuppression 
Panis et al. perfonned several studies with induction of tumour growth in the liver in which 
immunosuppression was induced by Cylosporin A'3,16,32. In one experiment they used a group of rats 
that had no detectable liver metastases 8 weeks after portal injection of colon carcinoma cells. They 
found a similar increase in development of liver tumours after PHx or after Cyclosporin A treatment 
within the same experimentl6 . However, a study by Ono et at. in mice disagrees with these findings 
since they found that PHx did not lead to stimulation of tumour growth but rather to growth inhibition. 
They transplanted 3 different tumour cell lines subcutaneously 3 to 10 days after PHx and found 
complete regression of a hepatoma cell line whereas no effect on tumour growth was seen on two 
other cell lines. Activation of killer cells and natural killer cells were in vitro induced by PHx, 
suggesting an immunostimulatory effect24. At least three other studies in mice oppose the findings of 
Ono et al. since they show an increased growth of subcutaneously implanted tumours in similar 
experiments with subcutaneous tumours2S-27. A recent study of Jarnagain et aI. 76 demonstrated an 
effect ofimmunomodulation on tumour growth after PHx. They found that neoadjuvant interleukin-12 
immunogene therapy protects against cancer recurrence. In experiments with colon adenocarcinoma 
CC531 immunosuppression could be an explanation for the observed effect of PHx since this tumour is 
weakly immunogenic77 . Our research group demonstrated earlier that CC531 exhibits enhanced growth 
when recipients are treated with Cyclosporine A 78. 
KupjJer cell function 
Kupffer cells are the representatives in the liver of the reticulo endothelial system (RES). Via 
the fonnation of glycoprotein, lymfokines and growth factors, Kupffer cells can direct the production 
of proteins by hepatocytes and their ability to proliferate. Kupffer cells are important for hepatocyte 
regeneration after PHx. In experiments with Kupffer cell-depleted rats the production of growth-
stimulating cytokines is imbalanced and liver regeneration impaired79. Kupffer cells are suggested to 
play a relevant role in arresting circulating tumour cells. They also seem to play a major role in 
clearing neoplastic cells from the liver parenchyma, in controlling tumour growth in the very early 
stages of metastatic development and in modulating the host immune response to cancer cells8o . Heuff 
et a1.35 found, in a liver metastases model with CC531 hlmour cells, that selective elimination of 
Kupffer cells resulted in a strongly enhanced growth of liver metastases. Karpoff et al l9 found that 
Kupffer cell stimulation by interferon '( (IFN-y) attenuated the tumour growth enhancement of PHx in 
vivo which, in vitro, is associated with a significant enhancement of Kupffer cell mediated tumour 
activity. Although not based on direct evidence it is tempting to speculate that PHx leads to a 
depression of the natural cytotoxicity nonnally exhibited by Kupffer cells, resulting in accelerated 
tumour growth. 
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Systemic treatment after partial hepatectomy 
The initial postoperative period after PHx is not only critical for the fonnation of metastatic 
lesions, but is also important for the regeneration of the resected liver. Applied anti tumour strategies 
during rat liver regeneration are listed in table 310,17,19,2UI.~2. 
Table3 Effects on tumour gro\\rth of adjuvant treatment during liver regeneration after 70% 
partial hepatectomy in rats. 
Reference Treatment Dose Schedule Result 
Ichihashi lO 1984 Mitomycin C 0.4 mg/kg 3x iv. Day 0 - 2 {. tumour in liver 
Mizutanj17 1992 Mitomycin C 0.2 mglkg 3x iv. Day 0 - 2 t tumour in liver 
5 fluorouracil 20 mglkg 3x iv. Day 0-2 t tumour in liver 
Karpoff 19 1996 IFNy 5xl04 U 4x i.p. Day -3 - 0; or .J.- tumour in liver 
Day 0 - 3 
Schindel2l 1997 Octreotide 50 Ilg/kg 2 dd, i.p. DayO-15 J... tumour in liver 
t tumour sucutaneously 
Daviessl 1997 Octreotide 2 ~g 2 dd, s.c. DayO-21 t tumour in liver 
Ikedas1 1998 Cilostazol 50 mg/kg 5x orally DayO-8 i survival 
(I) increased tumour growth. (Jj inhibition of tumour growth 
The initial period after PHx could theoretically be favourable for chemotherapy since the 
rapidly dividing tumour cells are more susceptible to several cytostatic agents and the tumour burden 
of occult metastases, after resection of the larger lesion, is low37.3s• Hmvever, adjuvant treatment 
aiming on reduction of tumour growth stimulation caused by PHx will also impair regeneration and is 
therefore not recommended clinically 83.84. Currently routine practice is to wait 4 weeks after resection 
before initiating adjuvant treatment for fear of detrimentally altering the process of altering DNA 
synthesis39 . Several reports on experimental studies with adjuvant chemotherapy during liver 
regeneration describe notable adverse side effects~5.86. 5-tluorouracil (5-FU) was found to reduce the 
tumour growth stimulation by 70 per cent PHx but also resulted in a lower wet weight of the 
remaining liver l7 . Mitomycin C (MMC) is found to be effective with less impact on regeneration. 
Therefore the effect of MMC may not be due to suppression of hepatic regeneration but to a direct 
cytocidal effect against rapidly dividing tumour cells 1o,17. Doxorubicin administered, by a single intra 
hepatic artery injection one day after 70 per cent PHx, did not increase survival. In this experiment 
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tumour cells were injected into the portal vein directly after PHx. In the same experiment, ciJostazol, a 
cyclic AMP phosphodiesterase inhibitor and a suppressor of platelet aggregation was found to increase 
survival when given 24 hours before PHx and tumour cell injection. This effect might be due to a 
decrease in tumour cell lodging which plays an important role in the early stages of development of 
metastases82 . 
IFN-y treatment 3 days prior to PHx attenuated the tumour growth enhancement. Growth factor release 
and liver regeneration were not affected. The effect of IFN-y on tumour growth is associated with 
significant enhancement of Kupffer cell mediated tumouricidal activity'9, 
The proinflarnatory cytokine tumour necrosis factor a (TNF-a) could be of benefit after PHx 
since TNF is known to stimulate rather than impair liver regeneration87•89• After PHx TNF-a is one of 
the earliest cytokines to be induced. It stimulates the production of other cytokines, including 11-6, 
which is required for hepatocyte proliferation87,9o. TNF-a has shown antitumour activity on colon 
cancer in rats91 , Therefore treatment with TNF-a could be an interesting option after Phx. However, in 
the clinical situation the use of TNF is limited to isolated perfusion because of severe toxicity after 
systemic administration92.93 , 
New treatment options 
Somatostatin analogues 
Octreotide, a long acting somatostatin analogue, was found to reduce the enhanced tumour 
growth by PHx in different models with intrahepatic - and subcutaneous tumours2 1.81. Octreotide is 
suggested to influence tumour growth in the regenerating liver through various pathways, Liver 
regeneration is reduced by octreotide treatment started before PHx, possibly by an indirect effect via 
suppression of insulin levels94 or inhibition of the release and end organ effect of many growth factors 
and cytokines95 . Octreotide increases hepatic RES activity probably by stimulation of Kupffer cells. 
Furthermore, portal pressure after 70 per cent PHx is reduced by continuous infusion of octreotide81 . 
The hrmour growth inhibiting effect of somatostatin analogues could also be caused by a direct effect 
on the tumour cells mediated through binding of the analogue to specific somatostatin receptors as was 
demonstrated by the present authors96 , Somatostatin receptors on tumours are in vivo demonstrated by 
somatostatin receptor scintigraphy in which a low dose of radiolabelled octreotide is used, This 
binding to the somatostatin receptor is highly selective. Therefore high doses of radiolabelled 
octreotide could theoretically have a local irradiation effect on the tumours as was demonstrated 
earlier97. The tumour growth inhibiting effect of octreotide and radiolabelled octreotide could be of 
benefit in patients with SS-R-positive tumours of which neuroendocrine tumours are the most 
common. 
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In patients with liver metastases of neuroendocrine tumours liver resections are perfonned 
with both curative and palliative intent98. While most tumour tissue in the liver is removed surgically 
adjuvant treatment can exert it's antitumour effect on residual intrahepatic tumour tissue and 
extrahepatic secondaries. However, if treatment with octreotide or radiolabelled octreotide after PHx 
demonstrates an antitumour effect it is important to investigate the effects on liver regeneration since 
octreotide is reported to suppress liver regeneration which could impair functional recovery 
clinically81.99. 
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CHAPTER 7 
TUMOUR GROWTH STIMULATION AFTER PARTIAL 
HEPATECTOMY CAN BE REDUCED BY TREATMENT 
WITH TUMOUR NECROSIS FACTOR 
The Brittish Journal o/Surgery 1995; 82: 129~132 
G.D. SLooter, R.L. Marquet, J. Jeekel and J.NM. Uzermans 
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Abstract 
This study investigated whether partial hepatectomy enhances the growth of experimental 
liver metastases of colonic carcinoma in rats and whether treatment with recombinant human tumour 
necrosis factor (TNF-a.) can reduce this increased growth. Resection of 3S or 70 per cent of the liver 
was perfonned in inbred WAG rats with sham operated controls. Immediately after surgery 5 x 105 
CC531 colonic tumour cells were injected into the portal vein. After 28 days the animals were killed 
and the number of liver metastases counted. A 35 per cent hepatectomy induced a significant increase 
in the number of liver colonies (median 28 colonies, versus 3 in controls), whereas a 70 per cent 
resection provoked excessive growth, consistently leading to more than 100 liver metastases and a 
significantly increased wet liver weight in all animals. TNF-a was given intravenously to rats 
following PHx 70% or sham operation in a dose of 160 ~g/kg, three times per week until sacrifice. 
Treatment with TNF-a was only marginally effective on tumour development in sham operated rats, 
but was very effective following 70 per cent hepatectomy or sham operation in a dose of 160j.lg/kg 
three times per week. This had only a marginal effect on tumour development in sham operated rats 
but was very effective following partial hepatectomy (median 45 liver metastases). These observations 
confirm previous findings that surgical metastasectomy may act as a 'double-edged sword' by 
provoking outgrowth of dormant tumour cells and suggest that adjuvant treatment with TNF-a may be 
of benefit in patients undergoing resection of metastases. 
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Introduction 
Surgical excision by partial hepatectomy is the only available method to prolong survival for 
patients with hepatic metastases from colorectal carcinoma. The 5-year survival rate of patients that 
are eligible for surgical resection (i.e. those with a solitary metastasis or small tumour burden confined 
to the liver) is 25-40 per cent!·4. These results compare favourably with the natural outcome for this 
selective group of patients, who have a 5-year survival rate ofless than 1 per centl,4. However, despite 
the curative potential of hepatic resection, recurrence has been reported in 65-80 per cent ofpatients2-4, 
the majority being diagnosed within the first year after operation2.}. This suggests that the first period 
after resection may be of crucial importance for prognosis. 
It is obvious that the favourable survival rates achieved by surgery validate a continued policy 
of resection of metastatic liver disease. On the other hand, the high number of early recurrences 
suggests that resection might provoke enhanced tumour growth of occult metastases. Experimental 
research may provide clues for a modified surgical strategy or appropriately timed adjuvant therapy. 
Several groups have found experimental evidence for tumour growth stimulation by partial 
hepatectomy in various animal models; both intrahepatic lesions and subcutaneously transplanted 
tumours were found to grow more quickly after this operations.9 . There are various explanations for 
this phenomenon. Growth factors produced by the regenerating liver, such as hepatocyte growth 
factor, transfom1ing growth factor-13 and epidennal growth factor, have been implicated as tumour 
growth promoting agents!O-12. Other possible mechanisms include the detrimental effect of surgical 
manipulation 13, the generalised immunosuppression provoked by partial resection 14, and impaired 
Kupffer cell function 15. 
The aim of the present study was to investigate whether evidence could be found for enhanced 
growth of fresh liver metastases after partial resection in a rat model of colonic adenocarcinoma. 
Furthennore, it was investigated whether the putative growth stimulation could be inhibited or 
reversed by adjuvant treatment TNF-a, an agent with proven efficacy against the colonic tumour 
under investigation 16. 
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Materials & Methods 
Animals and Tumour 
Male inbred WAG rats, 10-14 weeks old, weighing between 250 - 275 g, and bred under 
specific pathogen-free conditions were used. The rats were given standard rat food and water ad 
libitum. The experimental protocol adhered to the mles laid down by The Dutch Animal 
Experimentation Act and was approved by the Committee on Animal Research of Erasmus University. 
Tumour CC531 is a moderately differentiated, weakly immunogenic colonic adenocarcinoma, induced 
in a WAG rat by 1,2-dimethylhydrazine17 • The tumour is maintained in tissue culture as a monolayer 
in RPM! 1640 medium (Gibco, Paisley, U.K.), supplemented with 5 per cent fetal calf serum. A total 
of 5 x 105 cultured tumour cells were injected into the portal vein. The cells were harvested from 
stationary cultures by gentle trypsinisation, providing cell suspensions with a viability greater than 95 
per cent. Tumour CC531 is relatively insensitive to chemotherapy, but sensitive to the effects of 
biological response modifiers like the interferon-inducer Bropirimine, Interferon y and TNF_a16 . 
Experimental procedure 
Under ether anaesthesia the abdomen was opened through a midline incision. The left lateral 
and median liver lobes, representing 70 per cent of the liver volume, were freed of fibrous attachments 
and exteriorised. The circulation in these lobes was temporary intemlpted by ligation of the hilar 
vessels. CC531 tumour cells in 0.2 ml. RPMI 1640 were injected into the portal vein through a 0.4 x 
12 mm. needle. Over 2 minutes the tumour cells were directed through the remaining 30 per cent of 
the liver that was not ligated. The rats were then randomised into a partial hepatectomy group and a 
non-hepatectomy (sham) group. In the 70 per cent hepatectomy group the temporary ligation was 
replaced by a pennanent 2/0 silk tie and the ligated lobes were resected. In the 35 per cent 
hepatectomy group only the left lateral lobe was resected. In the sham group the temporary ligation 
was removed to re-establish the circulation. The liver was then rehtrned to the peritoneal cavity and 
the laparotomy wound closed in one layer. 
Rats were killed after 28 days by an overdose of ether. The liver was removed, immersed in 
phosphate buffered saline (PBS), and htmour growth was determined by counting the number of 
colonies at the surface of the liver lobes. The livers were put on blotting paper for 30 seconds to 
remove excess of PBS and were than weighed immediately. Experimental groups contained five to 
eight animals. 
Tumour Necrosis Factor a 
TNF-a was provided in lyophilized form by Knoll (Ludwigshafen, Germany). The product 
was 99 per cent pure, contained less than 10 pg. of endotoxin per mg protein and had a specific 
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activity of 6.63 X 106 Units/mg. It was reconstituted in PBS prior to injection and was given 
intravenously in a dose of 160 ).1g/kg in 0.2 ml PBS, three times per week, starting on the day of 
operation. Control treatment consisted of 0.2 ml PBS according to the same schedule. On completion 
of sham operation or 70 per cent hepatectomy the rats were randomised and assigned to control or 
TNF -u treatment. 
Statistical analysis 
The number of tumour colonies at the surface of the liver lobes was counted. When more than 
100 metastases were present, the number was scored as >100. Data were analysed with the Mann-
Whitney U-test for comparison of non-parametric data and expressed as median (range). The mean 
liver weight was compared using Student's unpaired t test. Significance was accepted at p < 0.05. 
Results 
Effect of partial hepatectomy 011 tumour growth 
The number of metastases 28 days after 35 or 70 per cent hepatectomy are shown in table 1. 
A 35 per cent resection induced a significant increase in the number of metastases (p=0.044) but not in 
wet liver \\.'eight. The number of colonies in the control group ranged from 0 to 20 (median 3), and 
from 10 to 57 (median 28) in the 35 per cent hepatectomy group. A 70 per cent resection induced an 
even greater increase in tumour development. In all rats receiving this operation the number of tumour 
colonies exceeded 100, whereas that in controls ranged from 0 to 31 (median 7). 
Table 1 Liver metastases and wet liver weight 28 days after tumour cell injection. 
No. of metastastases 
Operation Incidence Median (range) 
30 % PHx 60f6 > 100 
Sham* 50f6 7(0-31) 
70 % PHx 50f5 28 (10 - 57)t 
Sham* 50f6 3 (0 - 20) 
* Remaining lobes ligated during injection of tumour cells, but not removed. 
t p < 0.05 versus sham (A/ann - Whitney U test) 
t p < 0.05 versus sham (Student's t test) 
Wet liver weight (g) 
Mean (S.D.) 
22.5 (8.9)t 
10.6 (0.9) 
10.5 (1.3) 
10.2 (0.3) 
Following 70 per cent hepatectomy there also was a significant increase in wet liver weight 
(p= 0.006). The experiment involving 70 per cent resection was repeated four times showing similar, 
significant results. Figure 1 shows the explosive tumour growth in a 70 per cent resected liver and can 
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be compared with the appearance of a control liver in figure 2. In sham operated rats no tumour was 
ever found in the lobes ligated during the tumour cell injection. 
Figure 1 
Figure 2 
Antitumour effect ofTNF-a 
The results of treatment of sham operated and 70 per cent hepatectomised rats with TNF-a are 
shown in table 2. In the sham operated group treatment with TNF-a had no significant effect on 
tumour grmvth compared with that in non-treated sham operated controls (0-7 versus 0-> 1 00 colonies 
respectively). Following 70 per cent resection, treatment with TNF-a was very effective and resulted 
in a significant inhibition of tumour growth: range 5-> 1 00 (median 45) tumours in the treated group 
versus> 100 colonies in all non-treated animals. The decrease in tumour load following TNF-a 
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treatment was confirmed by a significantly decreased mean(S.D.) liver weight (12.4±6.5 versus 
22.4±8.4 g, respectively). Clinical signs of toxicity due to TNF-u treatment were not observed. 
Table 2 Effect of tumour necrosis factor u on growth of liver metastases 28 days after 70 per 
cent hepatectomy or sham operation. 
Treatment/Operation 
TNF -u treatment 
70 % PHx 
Sham* 
Control treatment 
70 % PHx 
Sham* 
Incidence 
60f6 
20f5 
50f5 
50f8 
TNF-a: tumour necrosis factor-a 
No. of metastases 
Median ( range) 
45 (5 - >IOO)t 
0(0 -7) 
> lOOt 
3.5 (0 - > 100) 
* Remaining lobes ligated during injection of tumour cells. but not removed. 
t p < 0.05 versus sham and 70 per cent hepatectomy control treatment 
:t P <0.05 versus sham (Mann-Whitney U-test) 
§ p < 0.05 versus sham (Student's t test) 
Discussion 
Wet liver weight (g) 
Mean (S.D.) 
12.4 (6.4) 
9.0 (0.6) 
22.3 (8.4) § 
8.7 (1.2) 
The first finding in these experiments is that partial hepatectomy provokes increased tumour 
growth in the liver remnant. In repeated experiments an increase was found in wet liver weight and in 
the number of tumours after partial hepatectomy. To investigate whether the degree of growth 
promotion was proportional to the size of the resection, the effects of 70 per cent and 35 per cent 
hepatectomy were compared, and it was found that this was indeed the case. Although both procedures 
significantly increased tumour growth, the effect of a 70 per cent resection was far greater. These 
findings confirm previous results obtained with various tumour models in rats5-9 . Using the same 
CC531 tumour model as described in the present study de long et al.(personal communication) 
recently found that partial hepatectomy also enhanced the growth of established liver metastases. It 
thus appears that, in this model, partial resection affects not only the outgrowth of fresh artificial 
metastases but also the proliferation of established tumours, thereby milToring the clinical situation to 
an even greater degree. However, results of studies performed predominantly in mice disagreed with 
these findings, and showed that partial resection did not lead to stimulation of tumour growth but 
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rather to growth inhibition IS-20. The inhibition of growth observed in the latter models has been 
ascribed to the immunostimulatory effects of partial resection, whereas immunosuppression and the 
release of growth factors have been held responsible for the enhanced tumour growth in rats. In the 
present rat model a likely explanation for the observed effect of partial resection is 
immunosuppression. A previous study showed that tumour CC531, which is weakly immunogenic, 
exhibits enhanced growth when recipients are treated with the immunosuppressive drug 
cyclosporine21 . In addition Heuff et aZ22 , using exactly the same model as the present authors, found 
that selective elimination of Kupffer cells resulted in a strongly enhanced growth of liver metastases, 
similar to the explosive growth following partial resection in the present study. Although there is no 
direct evidence, it is tempting to speculate that partial resection leads to a depression of the natural 
cytotoxicity nonnally exhibited by Kupffer cells, resulting in accelerated tumour growth. 
There are different theories regarding the origin of new metastases in the liver that give rise to 
detectable recurrence. Tumour cells can spread from primary tumour cells in the liver remnant or from 
extrahepatic secondaries to fonn de novo metastases in the liver. Also, tumour cells that are spread 
during partial hepatectomy can settle again in the liverl. However, it is most likely that 
micrometastases not detected by preoperative or intraoperative screening grow out to form detectable 
metastases23.24• It has been suggested that most of the occult metastases are single tumour cells that are 
spread throughout the liver8. These donnant tumour cells could be triggered to start proliferating by 
changes in extracellular host factors. Liver regeneration after partial resection could provide such a 
trigger for metastatic growth. It is conceivable that, in this phase of tumour development adjuvant 
therapy would be particularly effective. 
Treatment with TNF-o:. was found to reduce the number of metastases in the liver remnant. 
The anti tumour effect was more prominent in the regenerating than in sham operated liver, suggesting 
that the process of regeneration provides optimal circumstances for TNF-o:. to be effective. However 
tumour growth in the sham operated livers was low, so finn conclusions on the relative inadequacy of 
TNF-o:. in non-hepatectomised livers can not be drawn. 
Earlier studies on the efficacy of adjuvant therapy following partial hepatectomy in the rat 
provided evidence that 5-tluorouracil (5-FU) and mitomycin C (MMC) both were effective in 
reducing the enhanced tumour growth9• However, whereas the effect of mitomycin was found to be 
due to direct antitumour cytotoxicity, that of 5-FU was indirect and could be ascribed to inhibition of 
liver regeneration. In the present study the inhibition of tumour growth by TNF-o:. was not likely to be 
due to inhibition of liver regeneration. A pilot study has shown that treatment with TNF-o:. in doses 
ranging from 10 to 160 I-lglkg on days 0 and 3 did not affect liver regeneration as assessed by wet liver 
weighing on day 6 after 70 per cent hepatectomy (unpublished results). In addition, repeated injections 
of TNF-o:. to hepatectomised and intact rats stimulates DNA synthesis in hepatocytes resulting in an 
increased liver cell mass2526. If confinned, these latter findings imply that, depending on dose and 
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timing of administration, TNF-a may show two opposing effects: inhibition of tumour growth on the 
one hand and a counterproductive stimulation of liver regeneration on the other. In the clinical 
situation this undesired effect might be annihilated by combining TNF-a with chemotherapy. 
The clinical results so far obtained with systemic administration of TNF-a have not met the 
expectations raised by numerous animal studies27 . The few studies perfonned with TNF-a in patients 
with colorectal cancer have provided no evidence of anti tumour efficacy2s.29. However, interest in 
using TNF-a clinically has recently been rekindled by the remarkable efficacy of locoregional 
treatment with TNF-a (combined with Interferon-gamma and chemotherapy), in patients with 
melanoma and sarcomas30.3J . In agreement with this new approach are the positive results obtained 
with locoregional treatment of liver metastases from colorectai cancer. Van der Schelling et al32 found 
stable disease after injection of TNF-a directly into liver metastases, whereas Mavligit and 
colleagues33 observed a 14 per cent partial tumour response following TNF-a infusion via the hepatic 
artery. These studies indicate that TNF-a has definite antitumour activity in colorectal cancer 
metastatic to the liver. This observation, combined with the results obtained in the present study, 
supports the notion that a combination of metastasectomy and iocoregional adjuvant therapy with 
TNF-a, preferably combined with chemotherapy may be of benefit for patients with liver metastases 
from colorectal cancer. 
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CHAPTER 8 
THE INHIBITORY EFFECT OF RADIOLABELLED 
OCTREOTIDE ON INTRAHEPATIC TUMOUR 
GROWTH AFTER PARTIAL HEPATECTOMY 
Submitted for publication 
G.D. Slaater, A. GJ Aalbers, WAF Breeman, CA. Hiemstra, 
R.L. Marquet, E,P, Krenning and CH.J van Eijck 
Abstract 
Most neuroendocrine tumours and several other tumours such as breast carcinoma and malignant 
lymphoma express somatostatin receptors. Lesions expressing these receptors can in vivo be visualised by 
receptor scintigraphy using low radioactive doses of the somatostatin analogue [llIIn-DTPAo]octreotide. 
The same agent given in a high radioactive dose can be used for peptide receptor radionuclide therapy 
(PRRT). The aim of this study was to evaluate whether PRRT with [lllln-DTPAo]octreotide is able to 
reduce tumour growth even under tumour growth stimulating conditions induced by partial hepatectomy. 
Rats underwent 70% partial hepatectomy (PHx) or sham operation. The development of hepatic 
metastases was detennined 21 days after direct injection of somatostatin receptor-positive (SS-R-positive) 
or SS-R-negative tumour cells into the portal vein. Groups of 8 or 9 animals that underwent PHx or sham 
operation were treated with octreotide 50)lglkg sc. twice daily or with 370 MBq C IIIn-DTPAo]octreotide 
iv. on day 1 and 8. Both treatments were compared to control treatment. Forty non tumour-bearing rats 
were used to detennine the influence of [Ill In-DTP A °Joctreotide therapy on liver regeneration after PHx. 
PHx induced an increase in tumour growth in all experiments (p<O.OI). Octreotide treatment 
did not influence tumour growth after PHx or sham operation. C11ln-DTPAo]octreotide could 
effectively reduce tumour growth in the liver of SS-R-positive tumours also under conditions of 
increased tumour gwwth as generated by PHx (p<O.O I). C I I In-DTPA o]octreotide was also effective on 
SS-R-negative tumours after PHx (p=O.OI) but not after sham operation. Furthennore, [IIIIn_ 
DTPA (J]octreotide therapy did not influence liver regeneration or liver function after PHx. 
PRRT with [IIIIn-DTPAoJoctreotide is effective in SS-R-positive tumours. During liver 
regeneration also the gwwth of SS-R-negative tumours is reduced. This effect is not induced by 
impairment of liver regeneration or liver function. Radionuclide therapy could therefore be a 
promising treatment modality for patients with symptomatic liver metastases of neuroendocrine 
tumours in combination with liver resection. 
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Introduction 
Somatostatin (SS) is a small regulatory peptide, produced by degradation of a precursor protein, 
which inhibits the release of various honnones and may act as neurotransmitter in the central nervous 
system!. Several experimental and clinical studies also suggest an antiproliferative effect of 
somatostatinand its ana!ogues2•8. Critical to these actions is the presence of somatostatin receptors (SS-R), 
which like other membrane receptors subserve two functions: (1) to recognise the ligand and bind it with 
high affinity and specificity, and (2) to generate a transmembrane signal that evokes a biological response. 
At least five different human SS-R subtypes (55t l_5) have been cloned9. All subtypes bind somatostatinwith 
high affinity, while their affinity for the somatostatin analogue, octreotide, differs considerably. Octreotide 
binds with high affinity to sst2 and sst5, to a lesser degree to SSt3, while no binding to sstl and SS4 occurs, 
SS-Rs have been demonstrated on a variety of human tumours and their metastases 10, The vast majority of 
human SS-R-positive tumours express sst2 11 , For the visualisation of SS-R-positive tumours in vivo 
somatostatin receptor scintigraphy with C 1 1 Indium-diethylenetriaminopenta-acetic acid (1IIIn_ 
DTPAo)]octreotide (Octreoscan®) is used and this technique has become an important diagnostic tool in 
the management of patients with SS-R-positive tumours l2-15 , 11[ln emits not only gamma rays, which can 
be visualised with a gamma camera, but also internal conversion- and Auger electrons with a medium to 
short tissue penetration (200-550 ).tm, 0,02-10 ).tm, respectively)16-[S, In vivo, [lllln-DTPAo]octreotide 
binds to the SS-R and the ligand, including [I [In, is internalised and transported into the lysosomes with a 
long residence time of 1 [lIn in the tumour cells (biological half life > 700 hrs )19.20. This internalisation by 
tumour cells of the radioligand in vivo is an important aspect for peptide receptor radionuclide therapy 
(PRRT), We previously reported the antiproliferative effect of PRRT with rl[IIn-DTPAo]octreotide on 
the growth of SS-R-positive CA-20948 pancreatic tumour cells in the liver. We demonstrated that this 
effect of PRRT is SS-R dependent since blocking the receptors with a high dose of non-radioactive 
octreotide reduced this growth inhibitory effect almost completely. Moreover, no effect was achieved with 
SS-R-negative CC531 colon carcinoma cells21 . 
Resections of hepatic metastases of gastroenteropancreatic (OEP) tumours, which are 
predominantly SS-R-positive, are mostly perfonned with palliative intent since in most cases, a diffuse 
pattern of metastases is present at laparotomy. As we demonstrated earlier, PHx stimulates tumour growth 
within the regenerating liver dramatically22. Therefore we wanted to see whether the effect of PRRT on 
the gruwth of intrahepatic tumours in a model with accelerated intrahepatic tumour growth was also 
effective. In addition, we studied whether this effect of PRRT on tumour proliferation after PHx could 
probably be due to inhibition of liver regeneration. The putative tumour growth inhibiting effect of PRRT 
after PHx could have implications for further clinical trials in patients with SS-R-positive tumours and 
liver metastases. 
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Materials & methods 
Animals 
Male rats of the inbred WAG and Lewis strain, which were 10-14 weeks old and 225-250 g 
(Harlan-CPB,Austerlitz, The Netherlands) were kept under standard laboratory conditions (12 hours 
light/I2 hours dark) and were given standard laboratory diet (Hope Fanus, Woerden, The Netherlands) 
and water ad libitum. The experimental protocol adhered to the rules laid down by the Dutch Animal 
Experimentation Act and was approved by the Committee on Animal Research of the Erasmus Medical 
Centre Rotterdam. 
Tumours 
The pancreatic tumour, CA-20948, was originally induced by azaserine23. The SS-R-positive 
UlmOlIT is of acinar origin and is transplantable in syngeneic Lewis rats. The tumour was transplanted and 
maintained in the liver by direct injection into the portal vein. To produce artificial liver metastases, 
tumours were excised from donor livers, cleaned from nonnalliver tissue and pressed through sieves with 
decreasing mess size. The resulting suspension was washed twice in RPMI 1640 (Gibco, Paisly, UK.). 
Viability was measured with trypan-blue exclusion (0.3% in a 0.9% NaCI-solution). A suspension of 2.5x 
1 06 living cells/mL was used for direct injection into the portal vein. 
Tumour CC531 is a SS-R-negative, 1,2 dimethylhydrazine-induced, moderately differentiated 
colon adenocarcinoma, transplantable in syngeneic WAG rats24. The tumour is maintained in tissue 
culture as a monolayer in RPMI 1640 medium supplemented with 5% fetal calf serum. The cells were 
harvested from stationary cultures by gentle trypsinisation. A suspension of 2.5x 106 living cells/mL was 
used for direct injection into the portal vein. The presence/absence of the SS-R on both tumour cell lines 
was determined by specific binding of[125r-Tyr']octreotide. This binding was demonstrated to membrane 
preparations of CA-20948 pancreatic tumour cells (ICso of 0.6 lLrvI and a Bma" 110 fmol per mg membrane 
protein), while no binding was found to the membrane preparations of the CC531 colon tumour cells 8. 
Radiolabelling and quality control of the radioligand 
[DTPAOjoctreotide (Pentetreotide, DRN 4920) and til InCI ) (DRN 4901, 370 MBq/mL in HCI, 
pH 1.5 - 1.9) were obtained from Mallinckrodt Medical (Petten, The Netherlands). Octreotide was a gift 
of Novartis, Preclinical Research (Easle, Switzerland). The labelling was perfonned by diluting the 
freeze-dried [DTPAo]octreotide in 1 mL saline and adding this to the IllInCb. Thirty minutes after the 
start of this procedure quality control was perfonned by instant thin layer chromatography with silica-gel 
and 0.1 M sodium-citrate, pH 5 as eluent, as described earlier 25. Labelling efficiency of [lllln_ 
DTPA o]octreotide was over 98 %. Each administration of the radioligand into the dorsal penis vein 
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consisted of 370 I\1Bq Illln labelled with 0.5 !Jg [DTPAo]octreotide, referred as 370 MEg [lllln_ 
DTP A o]octreotide. 
Experimental procedure in tumour-bearing rats 
Under ether anaesthesia the abdomen was opened through a midline incision. The left lateral 
and median liver lobes, representing 70% of the liver volume, were freed of fibrous attachments. The 
circulation in these lobes was temporary interrupted by ligation of the hilar vessels. Then 0.5 x 106 
viable, SS-R-positive CA-20948 cells, suspended in 0.2 mL RPMI 1640 were injected slowly into the 
portal vein through a 0.4 x 12-mm needle. During 2 minutes the tumour cells were directed through the 
remaining 30 per cent of the liver that was not ligated. The rats were then randomised into a 70 % 
partial hepatectomy group (PHx) and a non-hepatectomy group (sham). In the PHx group the 
temporary ligation was replaced by a pennanent 2-0 silk tie and the ligated lobes were resected. In the 
sham group the temporary ligation was removed 2 minutes after the injection to re-establish the 
circulation. At the end of both procedures the liver was returned to the peritoneal cavity and the 
laparotomy wound was closed in one layer. On day I after the operation rats from both PHx and sham 
groups were randomised into experimental and control groups. All rats were sacrificed 21 days after 
inoculation of tumour cells. The livers were removed, irrunersed in phosphate-buffered saline, dried and 
weighed. Tumour growth was detennined by two investigators counting the number of metastases on the 
surface of the liver lobes, while blinded for treatment modality, as described earlierl. In the parallel 
experiment the same procedure was perfonned when 0.5 x 106 viable, SS-R-negative CC53 1 cells were 
injected. Experimental groups contained 8 or 9 animals. 
Treatment with octreotide 
Sixteen rats were injected with SS-R-positive CA-20948 tumour cells into the portal vein. 
Eight rats were treated with octreotide (Sandostatin®) 50 J.lg/kg in 0.2 mL RPMI, subcutaneously in 
the neck. Treatment was given !\vice daily starting on the first day after the operation. Control 
treatment consisted of 0.2 mL RPM! injections according to the same schedule. 
Treatment with [If lIn-DTPAOjoctreotide 
Sixteen rats were injected with SS-R-positive CA-20948 tumour cells into the portal vein and, in 
a parallel experiment, 16 rats were injected with SS-R-negative CC531 tumour cells. Rats in the 
experimental groups were treated with 370 MEg rliIIn-DTPAo]octreotide into the tail vein on days 1 and 
8. Rats in the control groups were injected with vehicle, 0.5 J.lg (DTPA o]octreotide. 
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Effects of tllln-DTPA1]octreotide on liver regeneration 
Fourty non tumour-bearing WAG rats undef\vent PHx according to the procedure described 
above and rand01nised into PRRT- and control groups. Animals in the PRRT group were injected with 
370 MBq [IIIIn-DTPAo]octreotide iv., 24 hours after PHx. Rats in the control group were injected with 
0.5 ~g [DTPAo]octreotide iv. Of each group 4 rats were sacrificed at 2, 4,8, 16, and 32 days after PHx. 
Functional recovery of the liver was determined with Bromosulfalein (BSP) (C2oHgBr4Na20IOS2) 
clearance during 45 minutes26. One hour before sacrifice the animals were injected into the dorsal penis 
vein with 8 mg BSP per 100 g body weight. Blood samples were drawn from the tail at I and 45 minutes 
after the injection of BSP. BSP concentrations in these samples were determined by colorometry at 586 
nm wave length. Clearance ofBSP in 45 minutes is expressed as (l-(BSP level after 45 minuteslBSP level 
after 1 minute)) xlOO. 
Liver function analysis was performed by determining the serum levels of alanine 
transaminase, aspartate transaminase, y-glutamyl transferase, alkaline phosphatase, bilirubin, protein, 
and albumin. All livers were weighed and DNA synthesis was measured by the 5-bromo-5-
iododeoxyuridine (BrdU) labeling index. In short, 90 minutes before sacrifice, 50mg BrdU per kg 
body weight were administered intraperitoneally. Samples of the remnant liver were fixed and 
embedded in parafin. The labeling index of BrdU was expressed as the rate of 100 hepatocyte nuclear 
positivity in five fields at high power (x400). 
Statistical analysis 
Statistical analysis was perfonned using Mann-\Vhitney U-test on categorised outcomes. 
Statistical significance was defined at p<0.05. 
Results 
Ejfects of treatment with octreotide 
The results of octreotide treatment on the growth of SS-R-positive CA-20948 tumours in the liver 
are given in table 1. In sham operated animals there was no difference in tumour gruwth between 
octreotide treatment and controls, 21 days after tumour cell injection. As found in earlier experiments PHx 
resulted in a significant increase in tumour groVvth, compared to sham operation, in both octreotide treated 
animals and controls ( P< 0.01 )22. Octreotide treatment in rats that underwent PHx did not decrease 
tumour growth. 
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Table I The effect of octeotide on SS-R-positive liver metastases after sham operation or 70% 
partial hepatectomy. 
Treatment 
Sham operation 
Controls (n~8) 
Octreotide (n~8) 
70% PHx 
Controls (n=8)t 
Octreotide (n=8};: 
Liver weight (g) 
Mean (s.c. tn.) 
10.4 (0.9) 
10.1 (1.0) 
16.1 (4.3) 
14.8 (2.6) 
t:; (p < 0.0] ) vs. Sham operation 
Tumour score 
o 1+ 2+ 3+ 4+ 5+ 
3 3 
4 3 
2 6 
6 
Liver weight and number of animals with given range afhepatic metastases (8 animals per group), 21 days after 
sham operation or 70% partial hepatectomy and direct injection of SS-R-positive CA-20948 tumour cefls into 
the portal vein. Octreotide treatment was given subcutaneously, twice daily 50 flglkg. No sigmficant efJixl was 
found of octreotide treatment in sham operated animals or in 70% partial hepatectomised animals. 
F;flects qf P RRT with [' If In-DTPAOj octreotide 
The results of PRRT with 370 MEq C11In-DTPAo]octreotide on the growth of SS~R-positive 
CA-20948 tumours in the liver are summarised in table 2 . PRRT on days 1 and 8 induced a significant 
decrease in tumour growth in sham operated animals (p < 0.01). PHx again showed an increased tumour 
growth compared to sham operation ( p < 0.01 ). Under these conditions of increased tumour growth, 
PRRT also induced a decrease in tumour growth (p < 0.01). 
In the parallel experiment with SS-R-negative CC531 tumour cells (table 3). PHx increased 
tumour growth both in PRRT and control groups (p < 0.01) PRRT did not induce a difference in 
tumour growth in sham operated animals. However, there was a significant decrease of tumour growth 
by PRRT after PHx also for these SS-R~negative tumours (P = 0.01). In this experiment 1 rat died by an 
overdose of ether. Another animal died due to incomplete ligation of the hilar vessels. 
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Table 2 The effect of PRRT with Cll In-DTPAoJactreotide on SS-R-positive liver metastases 
after sham operation or 70% partial hepatectomy. 
Liver weight (g) 
Treatment Mean (s.e.m.) 
Sham oneration 
Controls (n~S) 17.3(3.1) 
PRRT (n~S) 10.1 (004) 
70% PHx 
Controls '(n~S) 23.0 (2.7) 
PRRT (n~S)' 9.3 (1.1) 
f (p < 0.01) vs. Sham operation 
+ (p < 0.01) vs. Controls 
Tumour score 
0 1+ 2+ 3+ 4+ 5+ 
2 5 
7 
S 
7 
Liver weight and number of animals with given range of hepatic metastases (8 animals per group), 21 days after 
sham operation or 70% partial hepatectomy and direct injection ojSS-R-positive CA-20948 tumour cells into 
the portal vein. PRRT with 370 MBq rIl11n-DTPAOjoctreotide, given on days 1 and 8, induced a significant 
reduction oj tumour growth both in sham operated animals and in 70% partial hepatectomised animals. 
Table3 The effect of PRRT with C IIIn-DTPAo]octreotide on SS-R-negative liver metastases 
after sham operation or 70% partial hepatectomy. 
Treatment 
Sham oneration 
Controls (n~9) 
PRRT (n~9) 
70% PHx 
Controls t(n~9) 
PRRT (n~7)' 
Liver weight (g) 
Mean (s.e.m.) 
14.1 (5.3) 
IS.5 (S.O) 
43.4 (8.0) 
30.S (5.6) 
t f (p < 0.01) vs. Sham operation 
t (p = 0.0]) vs. Controls 
Tumour score 
o 1+ 
2 
7 
2+ 
5 
5 
3+ 
2 
5 
4+ 5+ 
2 7 
2 
Liver weight and number of animals with given range of hepatic metastases (7 or 9 animals per group), 21 days 
after sham operation or 70% partial hepatectomy and direct injection of SS-R-negative CC531 tumour-cells into 
the portal vein. PRRTwith 370 MBq rlll]n-DTPA()joctreotide on days] and 8 induced a significant reduction of 
tumour growth after partial hepatectomy. No significant effect of PRRTwasfound in sham operated rats. 
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Effects oj PRRT on liver regeneration 
The influence ofPRRT on liver regeneration after PHx was investigated in non tumour-bearing 
animals. During the first 4 days there was a rapid increase in liver weight after which restoraton of liver 
weight was almost completed. No difference in wet liver weight was found after 2,4, 8, 16, and 32 days 
between rats that unden.vent PHx with or without PRR T (figure 1). There was also no difference in BrdU 
labeling index between these 2 groups at days 2 and 4 after PHx (figure 2). At later intervals in both 
groups labelled hepatocytes were only identified sporadically again without difference. Basic liver 
function tests after PHx showed no alteration by PRRT (data not sho"WIl). In adition, BSP clearance was 
not influenced by PRRT (figure 3). 
Figure 1 
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Peptide receptor radionuclide therapy with e llIn-DTPAo]octreotide and liver 
regeneration after 70 % partial hepatectomy. 
Restoration of liver weight after 70 % PHx at day=O 
-+- PRRT 
___ Control 
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o 8 16 
Time (days) 
24 32 
Liver weights oj 40 rats that underwent 70% partial hepatectomy. The il?fluence was studied oj PRRT 
with 370 MBq {'IIIn-DTPAOjoctreotide intravenously on day 1 compared to control treatment with 
saline. Groups oJ animals (n=4) were sacr(ficed on days 2, 4, 8, 16, or 32 after 70 % partial 
hepatectomy. 
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Peptide receptor radionuclide therapy with C llIn-DTPAoloctreotide and 
liver regeneration after 70 % partial hepatectomy. 
BrdU labeling index 
days post PHx 
c::::J control 
=PRRT 
Labelling index of hepatocytes in rats that underwent 70% partial hepatectomy. The influence was 
studied of PRRT with 370 MBq t 11 In-DTPAOjoctreotide intravenously on day 1 compared to control 
treatment with saline. Animals were injected 90 minutes b~fore sacrifice with 50 mg/kg BrdU Groups 
of animals (n=4) were sacrificed on days 2, 4, 8, 16, or 32 ajier 70 % partial hepatectomy. After 4 
days labeLLed hepatocytes were only identified sporadically. 
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Clearance of Bromosllljalein (BSP) in 40 rats that underwent 70% partial hepatectomy (PHx). The 
influence was studied ofPRRT'vvith 370 MBq rIl1ln-DTPA(]octreotide intra venously on day 1 
compared to control treatment with saline. The clearance of8 mg/kg BSP in 45 minutes was expressed 
as ( 1 - (BSP level after 45 minutes / BSP level after 1 minute) x 100. ESP clearance ·was measured 2, 
4, 8, 16, and 32 days after 70 % PHx in groups consisting of 4 animals per measure point. 
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Discussion 
Surgical excision of liver tumours represents the only curative treatment for primary and 
metastatic liver malignancies. For colorectal tumours the results of surgical resection compare favourably 
with the natural outcome for these selected groups of patientsn . However, despite the curative potential of 
hepatic resection, recurrence has been reported in 65-80 % of the patients. The predominant site of 
recurrence is within the remnant liver and the majority is diagnosed within the first year after the 
operation28.29• The high nl.llnber of early recurrences suggests that resection might act as a 'double-edged 
sword'. On one hand survival after PI-Ix is increased but on the other hand resection might provoke 
enhanced tumour gmwth. Clinical support for increased tumour gmwth after PHx was published recently. 
Elias et al.30 demonstrated that during liver regeneration following right portal embolisation the growth 
rate of liver metastases in the left liver lobes is increased and even more rapid than the growth of liver 
parenchyma. These findings are in agreement with studies in rats which demonstrate accelerated tumour 
growth in regenerating liver lobes and inhibited tumour growth in atrophied liver segments after selective 
portal embolisation31 . 
Several groups have found experimental evidence for stimulation of tumour grmvth by PHx in 
various animal models; both intrahepatic - and extrahepatic tumours were found to grow more rapidly 
after PHx32•37. We reported earlier, using the same model as in the present study, that the growth of SS-R-
negative CC53 1 colonadenocarcinoma tumours in the remnant liver after resection of70% of the liver rats 
was significantly increased compared to sham operated animals22. We then reported that tumour necrosis 
Factor 0. (TNF-a), administered intravenously, reduced this tumour growth stimulating effect of PHx. 
TNF-a could be of benefit after PHx since TNF-a is known to stimulate rather than impair liver 
regeneration3S.39 . However, in the clinical situation the use of TNF-a is limited to isolated perfusion 
because of severe toxicity after systemic administration40.41. 
If tumour growth is stimulated after PHx the number of replicating tumour cells will be 
increased. Theoretically this phase of tumour growth stimulation could be favourable for adjuvant 
chemotherapy, applied as adjuvant treatment, since the rapidly dividing tumour cells might be more 
susceptible to cytostatic agents. However, adjuvant treatment aiming at reduction of tumour growth 
stimulation caused by PHx might also impair liver regeneration and must therefore clinically be 
applied \vith great care for it is the regenerating capacity of the liver that makes patients able to 
recover from large resections 4~.43. Several reports on studies with adjuvant chemotherapy, including 
doxyrubicin and 5-fluorouracil, describe notable adverse effects caused by impainnent of liver 
regeneration 34.44.45. An effective adjuvant treatment that does not impair regenereration could 
therefore be of value for patients with hepatic metastases. 
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For neuroendocrine liver metastases, that are mostly SS-R-positive, clinical considerations are 
different since surgery is not only undertaken with curative intent but also for palliation. Cytoreductive 
hepatic surgery leads to sustained palliation of symptoms, reduces the need for additional treatment and 
prolongs survival in selected groups of patientsMi-so. Adjuvant strategies after liver resection could be of 
great value for patients with hepatic neuroendocrine tumours since (occult) residual tumour burden within 
the liver will be low after the resection. Of these patients with liver metastases of neuroendocrine tumours 
65 - 75 % have extrahepatic disease, as can be detected by scintigraphy14.S1. Development of effective 
adjuvant treatment after cytoreductive hepatic resection might make more patients eligible for surgery. 
The first finding from this Shldy is that the gro-wth of SS-R-positive pancreas carcinoma CA-
20948 tumours is increased by PHx to the same extent as we found earlier for tumour CC53 122.52. 
Therefore our model with PHx seemed appropriate to investigate the effect of octreotide and PRRT on 
SS-R-positive and SS-R-negative tumours during accelerated gro-wth. We did not find a reduction of 
tumour growth after PHx in our experiments using octreotide alone. However, we were able to 
demonstrate that PRRT with 370 MBg [lllIn_DTPAo]octreotide on day 1 and 8 significantly inhibits the 
growth of SS-R-positive CA-20948 tumours in the liver. After PRRT, both in sham operated and PHx 
animals there were only few tumour colonies present while control animals all had a large tumour 
burden in their livers after 21 days. In previous studies, in animals without PHx, we found that PRRT 
significantly decreased the growth of SS-R-positive tumours in the liver even when PRRT was 
perfonned 12 days after inoculation of the tumou('1.52. The nessecity of the SS-R for this tumour 
growth-inhibiting effect was proven since blocking the SS-R's by pre-treatment with octreotide reduced 
the effect ofPRRT almost completely. Moreover no effect was found on SS-R-negative CC531 tumours 
as also was fOWld in the current study for sham operated animals. Three other experimental studies with 
radiolabelled somatostatin analogues demonstrated the antiproliferative potential of PRRT on solid 
subcutaneously transplanted tumours, using [64Cu-TETAo]octreotide, [9Oy-DOTA,Tyr3]octreotide and 
188Re_RC_160, respectively53-ss. However, the effect of PRRT was never demonstrated for liver 
tumours. Recently the first results of PRRT with Cllin-DTPA~octreotide in patients with 
neuroendocrine tumours were documented using a cumulative dose of 74 GBq. There were no major 
clinical side effects and there were promising beneficial effects on clinical symptomes, honnone 
production and tumour proliferation. Of the 21 patients who received a cumulative dose of more than 
20 GBg eight patients showed stabilisation of disease and six other patients showed a reduction in 
tumour sizes6 . 
In this study we reconfirmed that PRRT has no significant effect on SS-R-negative CC531, 
therefore, no effect was expected after PHx. However, tumour growth was significantly reduced by PRRT 
after PHx also for this SS-R-negative tumour, albeit far less than observed for SS-R-positive ntmours. It 
could be that liver regeneration is impaired by PRRT as has been described for octreotide57,58. This 
putative inhibition of regeneration could also lead to less tumour gro-wth stimulation. Therefore, we 
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investigated the effect of PRRT on liver regeneration in non-tumour-bearing animals. PRRT was given 
one day after PHx since liver regeneration is most profound during the first 48 hours after pHx59. The 
restoration of liver weight was not found to be influenced. In both groups there was a fast increase in liver 
weight during the first days after PHx. At different time intervals up to 32 days, when complete 
restoration of liver volume is to be expected, no difference was found in wet liver weight. Also no 
difference in BrdU labeling index was found indicating that there was no difference in the number of 
regenerating hepatocytes. Functional recovery of the liver, studied by BSP clearance and basic liver 
function tests, was not different. Therefore we conclude that the decrease in tumour growth by PRRT after 
PHx is not caused by an inhibitory effect on liver regeneration. An explanation for the effect ofPRRT on 
SS-R-negative tumours could be that the neovasculature of regenerating livers express a high density of 
SS-R's as has been demonstrated in peritumoural veins in primary tumours and their metastases60.61 . The 
effect of PRRT on these SS-R-negative tumours could then be ascribed to accumulation of the 
radionuclide close to the tumour cells and the effect on angioneogenesis. 
This study demonstrates that PRRT can reduce increased tumour growth after PHx. This effect 
was very strong for SS-R-positive tumours, probably mediated through the SS-R, however also for SS-
R-negative tumours PRRT could reduce the increase of tumour growth. Liver regeneration is not 
impaired by PRRT nor the function of the remaining liver. This could imply that PRRT might be an 
effective option after PHx clinically. 
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CHAPTER 9 
SOMATOSTATIN RECEPTOR SCINTIGRAPHY IN 
PATIENTS WITH LIVER METASTASES OF 
NEUROENDOCRINE TUMOURS 
Submitted for publication 
G.D. Slaater, D.J. Kwekkebaam, S. W.A. Nij Bijvank, 
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Abstract 
Somatostatin receptors are present on most neuroendocrine tumours. Somatostatin receptor 
scintigraphy (SRS) with C11ln-DTPAo]octreotide (Octreoscan®) is a technique which has shown to 
localise the primary as well as intra- and extrahepatic metastatic disease of neuroendocrine tumours 
with a high sensitivity. For the optimal management of patients with liver metastasis of 
neuroendocrine tumours accurate imaging and staging is essential. The aim of the present study was to 
compare the value of conventional imaging methods (elM) and SRS in the diagnosis and staging of 
patients with proven liver metastases of neuroendocrine rumours. 
Forty-eight patients with liver metastases of neuroendocrine tumours detected by elM were 
referred to our hospital. Liver metastases of carcinoid tumours were found in 39 patients, in 5 of 
pancreatic islet cell tumours and in 4 of "non-functioning" endocrine tumours. The results of CIM and 
SRS in the detection of both intrahepatic- and extrahepatic tumours were compared. In 26 patients in 
which single photon emission computed tomography (SPEeT) was performed together with planar 
SRS the additional value of SPEeT imaging in the detection of intrahepatic metastases was 
detennined. 
With elM 50 extrahepatic tumours were detected in 22 patients, while with SRS 114 
extrahepatic tumours were detected in 37 patients. With planar SRS liver metastases were visualised in 
35 of the 48 patients (73%). In all 26 patients (100%) in whom both planar SRS and SPEeT were 
performed liver metastases were demonstrated. 
Planar SRS is superior in the detection of extrahepatic metastases of neuroendocrine tumours 
compared to the combination of conventional imaging methods. With SPEeT imaging additional to 
planar imaging with SRS liver metastases are demonstrated with high sensitivity. Therefore SRS with 
SPECT should be recommended as the first imaging method for the staging of patients with 
neuroendocrine tumours. 
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Introduction 
The optimal management of patients with neuroendocrine tumours (NETs) requires accurate 
imaging and staging. Proof of extrahepatic metastases will eliminate patients for curative liver 
resection or liver transplantation. Treatment of liver burden will then only be possible with palliative 
intent. In addition accurate localisation of intra- and extrahepatic tumours will make operative 
strategies more efficient. In the past therapeutic strategy was based on the results of conventional 
imaging methods (CIM) such as computed tomography (CT), ultrasound (US) and recently of 
magnetic resonance imaging (MRJ) in combination with bone scanning. For the visualisation of 
somatostatin receptor (SS-R) positive tumours like neuroendocrine tumours, somatostatin receptor 
scintigraphy (SRS) with r111Indium-diethylenetriaminopenta-acetic acid (1IIIn_ DTPA o)]octreotide 
(Octreoscan®) has been used for more than 10 years 1.2. There are two complementary imaging 
methods in SRS: planar SRS imaging which yields two-dimensional images with which extrahepatic 
localisations of primary and metastatic tumours can be identified and SRS-SPECT, in which a rotating 
camera is used, to make image reconstructions similar to computed tomography. This technique 
renders additional visual infonnation, especially on tumours in the liver and upper-abdomen3- j .The 
efficacy of SRS using [111 In-DTPA o]octreotide in patients with histologically or biochemically proven 
endocrine pancreatic tumours or carcinoids was evaluated in a European multicenter trial6. The highest 
success rates of SRS for the visualisation of primary tumours were observed with glucagonomas 
(100%), vipomas (88%), gastrinomas (73%), "non-functioning"islet cell tumours (82%) and 
carcinoids (87%). 
Three clinical studies have demonstrated the additional value of SRS to CIM, consisting of 
CT, US magnetic resonance imaging (MRI), selected angiography and endoscopic ultrasonography in 
patients with neuroendocrine tumours7-9• SRS in these studies altered clinical management in 21% to 
47% of the patients and had superior sensitivity and specificity compared to CIM. In these studies SRS 
was performed to identify primary tumours and intra- and extrahepatic metastases. The aim of the 
present study however, was to assess the value of planar SPEeT and SRS for the localisation of 
intrahepatic and extrahepatic tumour lesions in patients with histologically proven liver metastases of 
NETs. 
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Patients & methods 
A retrospective study of all patients with hepatic metastases of NETs analysed at OUf hospital 
betvveen 1989 and 1998 was perfonned. Forty-eight patients with liver metastases detected by either 
abdominal ultrasound or spiral CT underwent SRS. Evidence of neuroendocrine origin of these 
metastases was rendered by histological examination of liver biopsies or resection specimen. 
Conventional imaging methods (elM) consisted of abdominal trifasic spinal CT scanning, at 5 
em thickness and with oral contrast, and US of upper abdomen in all patients. Chest CT was added in 
7 patients, bone scintigraphy in 3 and colonoscopy in 2 because clinical symptoms were suspect for 
metastatic disease. Before 1992 SRS was performed only planar in 22 patients; thereafter planar SRS 
was combined with SPEeT imaging of the abdomen in 26 patients. Of all 48 patients the reports of 
elM were compared with the reports of SRS. The time between the investigations was less than 30 
days. Extrahepatic lesions were scored in total numbers of tumours and number of regions of the body 
affected. The body was therefore divided into 6 localisation segments: head and neck, thorax, upper 
abdomen (above lower kidney poles), lower abdomen (beneath lower kidney poles), spine and 
extremities. If multiple tumours were visualised at one location this was scored only once. The 
sensitivity for the detection of intrahepatic lesions was determined in patients that had only planar SRS 
performed and in patients that had both planar SRS and SRS SPEeT performed. For the 26 patients 
that had both planar SRS and SRS SPEeT performed, the images were reviewed to score the 
additional value of SPEeT imaging to planar SRS for the detection of intrahepatic metastases. 
Scanning protocol 
Planar images were obtained with a double head or large field of view gamma camera, 
equipped with medium-energy parallel-hole collimators, 24 h after injection of 220 MBq ['llIn_ 
DTPAo]octreotide (Mallinckrodt, Petten, the Netherlands). Windows were centred over both IllIn 
photon peaks (172keV and 245 keY) (window width 20%). The acquisition parameters for planar spot 
view images were 3000,000 pre-set counts or 15 min per view for the head and neck, and 500,000 
counts or 15 min for the remainder of the body. Repeat scintigraphy after 48 h was performed for the 
abdomen to differentiate radioactive bowel content from presumed pathology. For SPECT images 
with a triple-head camera the acquisition parameters were: 40 steps of 3 degrees each, and 30 sec per 
step. SPECT analysis was performed with a Metz filter on original data. 
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Results 
Origin of liver metastases 
Forty-eight patients were evaluated of whom 39 (81%) had liver metastases of carcinoid 
tumours, 5 of pancreatic islet cell tumours, and in 4 patients liver metastases were present of "non-
functioning" neuroendocrine tumours. All patients had intrahepatic tumours demonstrated by elM. In 
24 patients the primary tumour had been surgically removed previously. 
Detection of extrahepatic tUmours 
With SRS extrahepatic tumours were detected in 37 patients while with elM extrahepatic 
tumours were detected in 22 patients. In 15 patients SRS was the only imaging method to detect 
extrahepatic tumours while SRS detected extrahepatic tumours in all patients that had tumours 
detected by elM (table 1). This means that SRS detected extrahepatic tumours in 58 % of the patients 
in which extrahepatic disease could not be demonstrated by CIM. 
SRS showed 114 extrahepatic tumours at 86 different localisations in 37 patients whereas CIM 
showed 50 extrahepatic lesions at 33 localisations in 22 patients. The results, listed in table 2, 
demonstrate that SRS detected significantly more tumours at different localisations in 68 % more 
patients than CIM. 
Table 1 
SRS Positive 
SRS Negative 
Detection of extrahepatic metastases elM VS. SRS. 
Number of patients 
CIM Positive 
22 
elM Negative 
15 
11 
Total 
37 
11 
48 
The localisations at which extrahepatic tumours were found with SRS or elM alone or both 
elM and SRS are listed in table 3. The total number of local is at ions was 91 of which SRS was the 
only imaging method in 60. In 24 patients the primary tumour had been removed surgically. In 13 
patients the localisation of the primary tumour was not demonstrated with SRS. In 11 patients the 
primary tumour was known and identified with SRS. 
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Detection 0/ intrahepatic tumours 
In table 4 the detection of intrahepatic tumours is listed. In 22 patients only planar SRS was 
perfonned. In 17 of these 22 patients the presence of intrahepatic tumours was found. In 26 patients 
both planar SRS and SRS SPECr were perfonned. Re-examination of planar SRS and SRS SPECr in 
this group of 26 patients demonstrated that planar SRS demonstrated intrahepatic rumours in 18 
patients. So with planar SRS in the group of 48 patients liver metastases were found in 35 (73%). With 
the addition ofSRS SPECr intrahepatic tumours were demonstrated in all 26 patients (100%). 
Table 2 Detection of extrahepatic metastases CIM vs. SRS. 
Imaging method No. of patients No. of tumours No. of localisations 
elM 
SRS 
22 
37 (+68%) 
50 
114 (+128%) 
33 
86(+161%) 
Comparison between conventional imaging methods (CIM) and somatostatin receptor scintigraphy (SRS) in the 
detection 0/ extrahepatic metastases in 48 patients with liver metastases 0/ histologically proven neuroendocrine 
lumours. Table shol-}-s the number o/patients in whom extrahepatic metastases were demonstrated, the number 
a/tumours detected and the number a/localisations at which tumours Ivere found. The number a/additional 
patients, tumours and localisations detected by SRS are expres!ed in percentages. 
Table 3 Localisations of extrahepatic metastases elM vs. SRS. 
Head and neck 
Thorax 
Upper abdomen * 
Lower abdomen 
Spine 
Extremities 
Total 
elM only 
3 
5 
elM + SRS 
3 
6 
8 
5 
2 
2 
26 
SRS only 
5 
14 
14 
14 
5 
7 
60 91 
Comparison between conventional imaging methods (CIM) and somatostatin receptor scintigraphy (SRS) in the 
detection a/extrahepatic metastases in 48 patients with liver metastases a/histologically proven neuroendocrine 
lumours. Table shows the number Qfpatients in vvhom extrahepatic metastases were demonstrated at the 6 
localisations listed. The total number 0/91 localisations 'was found. SRS was the only imaging method to identifY 
these localisatialls in 60 (66%) whereas SRS did not demonstrate lesionssu,spected fo be metastases by C1M at 5 
localisations 5 (5%). * The abdomen is divided into upper abdomen and lower abdomen by the imaginary line 
connecting the lower poles o/the kidneys. 
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Table 4 Detection of intrahepatic metastases somatostatin receptor scintigraphy. 
Yes 
No 
Total 
Planar only 
17 
5 
22 
Planar only 
18 
8 
metastasis somatostatin receptor scintigraPJ) 
Planar + SPECT 
26 
26 
intrahepatic tumours conventional imaging methods(CIM). 22 patiens 
pelfonned only and 26 patients had both SRS-planar and SRS-SPECT pelformed. III the patients 
SRS-planar and SRS-SPECT performed intrahepalic tumours were found ill all patients. Review of the images in 
the group that had both SRS-planar and SPECT pel/ormed demonstrated that ill 8 of the cases the intrahepatic 
tumours were 110t detected SRS-planar only. 
Table 5 Imaging methods for the detection of liver metastases and extra-hepatic metastases in 
patients with Zolinger-Ellison syndrome. 
Procedure 
Ultrasonography (US) 
Computed tomography (CT) 
Magnetic resonance imaging (MRI) 
Angiography (Angio) 
US + CT + MRI + Angio (CIM) 
SRS 
SRS +CIM 
SRS Only* 
elM Only** 
Gibril et at. Ann Intern Med 1996; 125:26-34 
Positive result (%) 
Extra-hepatic tumour 
(/1 ~ 80) 
9 
31 
30 
28 
48 
58 
68 
20 
10 
Liver metastases 
(/1~24) 
46 
42 
71 
62 
83 
92 
96 
12 
4 
Results of tumour iocalisation/or the identification o.fliver metastasis and an extra-hepatic tumour in patients 
with Zollinger-Ellison syndrome. Results are expressed as the percentage oJthe 24 patients with proven liver 
metastasis and o.f the 80 with extrahepatic disease. 
Conventional imaging methods (elM) included ultrasonography. computed tomography( CT). magnetic 
resonance imaging (MRl) and angiography. 
* Tumour detected on(v with somatostatine receptor scintigraphy (SRS) 
** Tumour detected only with CIM 
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Discussion 
Several research groups have demonstrated the additional value of SRS in the diagnosis of 
NETs. Their studies included patients with and without liver metastases. In a prospective study from 
the National Institutes of Health, Bethesda, comparing the sensitivity of SRS with that of CT-
scanning, MRI, US and selective angiography in the detection of primary and metastatic gastrinomas, 
SRS altered clinical management in 47% and had a superior sensitivity, and specificity (table 5)7,10. At 
the Hopital Bichat - Claude Bernard, Paris the results of SRS were compared with the results of CIM 
including endoscopic US, and with surgical findings in 21 consecutive patients with Zollinger-Ellison 
syndrome ll . SRS added complementary information to other imaging techniques including endoscopic 
US and improved the preoperative detection of extrapancreatic gastrinomas. By combining SRS with 
endoscopic US they were able to detect 90% of the tumours in the upper duodenopancreatic area. SRS 
identified metastatic disease in 20-30% of patients after all other imaging techniques had failed3• In 
their prospective study concerning 160 patients with neuroendocrine gastroenteropancreatic (GEP) 
tumours including carcinoid and pancreatic islet cell tumours, Lebtahi et al. described that SRS 
changed the surgical therapeutic strategy in 40 (25%) patients. Unsuspected liver tumours were 
discovered only by SRS in 7 patients, contralateral liver tumours before hepatecomy in 2 and 
extrahepatic disease in 31 patients." A study from the Institutio Nazionale Tumori, Milan, 
demonstrated a modification of scheduled treatment by SRS in 21 % and a detection of previously 
unknown tumours in 28 % of the patientss. 
The aim of our study was to stage patients with proven hepatic metastases of NETs more 
accurately in order to improve clinical management. First of all we demonstrated that SRS is superior 
in the detection of extrahepatic tumours compared to the combination of CIM which consisted of 
abdominal CT and US in all patients and additional chest CT, bone scintigraphy and colonoscopy in 
some patients. In 15(31%) of the 48 patients investigated, SRS was the only imaging modality to 
detect extrahepatic metastases. Our results are in agreement with two other studies in which SRS 
demonstrated extrahepatic metastases in 22% and 54% of the patients that had no evidence of 
extrahepatic tumour with other imaging techniques9, 12. For these patients treatment by means of liver 
resection only would not be curative and the detection of extrahepatic disease furthermore excludes 
these patients for liver transplantation. The great advantage of whole body planar scintigraphy is that 
with one single method 'whole body' imaging is obtained (i.e. from head to pelvis), and that this 
includes information on possible metastatic sites that are not usually investigated by CT, US, and 
MRI. Also, the nature of SRS, which is based on the presence of SS-Rs on the tumour cells, instead of 
the criterion of tissue invasion or Iymphnode enlargement, which is identified in CIM, may yield 
additional information. This explains that with SRS in our group of 48 patients 60 additional tumour 
localisations were visualised which had not been detected with CIM. Interestingly bone metastases in 
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extremities and spine were demonstrated in 16 (33 %) patients with liver metastases. Gibril et al. 
detected bone metastases in 31 % of the patients with liver metastases from gastrinomas. Lebtahi et a1. 
found similar accuracy of SRS and bone scintigraphy for the detection of bone metastases in patients 
with NETs13. Because bone metastases can occur initially outside the axial skeleton, SRS is 
recommended the initial localization method of choice to screen for bone metastases in patients with 
liver metastases of NETs. Patients with pancreatic endocrine tumours with liver metastases should 
undergo SRS every 6 months to 1 year to detect bone metastases l4. 
Because there is a relatively high uptake in liver and kidney, the interpretation of planar SRS 
in the upper abdomen and especially within the liver is difficult. With the addition of SPECT imaging, 
the upper abdomen can be analysed with higher sensitivity4. In the group of 26 patients with proven 
liver metastases in our study in all patients intrahepatic tumours were detected by SPECT and in only 
18 patients (72%) with only planar SRS which demonstrates the importance of systematic SPECT 
imaging in the management of patients with NETs. 
Since 37 patients in our series (77%) were found to have extrahepatic disease and another 7 
(16%) multiple bilateral liver metastases, most patients were no candidates for curative liver resection 
or transplantation and should be treated systemically. Clinical studies in patients with hormone 
producing islet cell tumours showed a close parallel behveen the presence of SS-Rs on the tumours 
and the in vivo and in vitro suppressive effects of octreotide on honnone release l5 • This indicates that 
SRS can predict a possible suppressive effect of octreotide on hom10nal hypersecretion by endocrine 
pancreatic tumours. The observation that somatostatin inhibits the release of various peptide hormones 
has stimulated the interest in its use as an antiproliferative agent. In preclinical studies somatostatin 
analogues inhibit the growth of a wide variety of SS-R positive as well as SS-R negative tumours in 
vivo and in vitro I6 -18 • The results of clinical trials in patients with NETs, using somatostatin analogues 
alone or in combination with interferon-a are rather disappointing with a biochemical response in 77% 
of patients with a median duration of 15 months but without reduction in tumour size I9-21 • Octreotide 
has been clinically the most cOlmnonly applied somatostatin analogue, yielding biochemical response 
rates between 30 -70 % but objective tumour shrinkage in less than 2%-7% of the patients22-26• 
A new application is the use of radiolabelled octreotide for peptide receptor radionuc1ide 
therapy (PRRT) in patients with disseminated neuroendocrine tumours. After systemic injection of 
ellIn-DTPAoJoctreotide the radionuclide is specifically internalised and transported into the 
lysosomes27.2s. I11In not only emits gamma-rays, which can be visualised during scintigraphy, but also 
internal conversion- and Auger electrons having a medium to short tissue penetration (200-550 !J.m, 0.02-
10 !J.m, respectively). Therefore, an effect on tumour cell proliferation could be expected, as the 
radiotoxicity of the radionuc1ide is very high if the DNA of the cell is within the particle range29.30 . 
Experimental studies demonstrated tumour growth-inhibition of solid subcutaneous tumours by 
radiolabelled somatostatin analogues in animal models31 -33 • We demonstrated in a liver model that the 
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antiproliferative effect of [lllIn-DTPAo]octreotide is dependent on the presence or abundance of the SS-R 
which can be clinically demonstrated by SRS2. 
A phase 1 study on the side effects and antiproliferative effect of high, multiple 
radiotherapeutic doses of [I I IIn-DTPA °Joctreotide started in 199535.36. Twenty-one patients received a 
total cumulative dose of at least 20 OBq [I I 1 In-DTPAo]octreotide with a maximum of75 GBq. With a 
maximum follow up of 26 months no major clinical side effects were observed except for a transient 
decline in platelets count and the number of white blood cells. Kidney function was only influenced 
slightly and without clinical relevance. Impressive effects on the clinical condition of the patient and 
hOlTI1one or tumour marker production were observed after the administration of high doses of C llIn_ 
DTPAo]octreotide. Prior to the start of treatment all 21 patients had progressive disease. In 8 patients 
treatment resulted in stable disease and in 6 patients in actual tumour shrinkage, monitored with CT or 
MRI. In these patients beneficial effects on hOlTI1one production and clinical symptoms were found. 
SRS in these patients predicted the clinical result since a better result of PRRT was observed in 
patients whose hlmours has a high accumulation of the radioligand on their staging SRS scintigram. 
Our findings are in agreement with the results of other repofts on radionuclide therapy with C IllnM 
DTPAoJoctreotide that have described smaller groups of patients with end stage NETs37-41 • 
We conclude that SRS plays a crucial role in the staging and managemant of patients with 
NETs since we found that SRS detected extrahepatic tumours in 58% of patients in which extrahepatic 
disease could not be demonstrated by elM. In addition SPEeT imaging of the upper abdomen renders 
a high sensitivity for intrahepatic tumour detection. Therefore, planar SRS with SPEeT imaging 
should be recommended as the first imaging method in patients with neuroendocrine tumours. With 
proof of extrahepatic tumours patients with liver metastases will be excluded for curative liver 
surgery. Systemic PRRT with radiolabelled somatostatin analogues for these patients could become a 
promising treatment modality in the future. 
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CHAPTER 10 
SUMMARY AND CONCLUSIONS 
SAMENVATTING EN CONCLUSIES 
Summary 
The aims of this thesis were to investigate the possibilities of anti tumour therapy with 
octreotide and radiolabelled octreotide in the rat. We also shldied a hlmour growth stimulating effect 
of liver regeneration after partial hepatectomy. Since, if this putative tumour growth stimulation by 
partial hepatectomy could be demonstrated we wanted to see whether treatment with octreotide and 
radionuclide therapy could be effective after hepatectomy and whether this treatment would influence 
liver regeneration. In addition we wanted to investigate the value of somatostatin receptor scintigraphy 
in patients with liver metastases of neuroendocrine tumours to define patients that could possibly 
benefit from peptide receptor radionuclide therapy. 
Chapter 2 gives a review on somatostatin receptor expression and the use of somatostatin 
receptor scintigraphy in patients with neuroendocrine tumours. The clinical use of somatostatin 
analogues in the treatment of neuroendocrine diseases and the oncological applications of somatostatin 
analogues are described. An introduction is given on new treatment options for patients with 
neuroendocrine tumours with peptide receptor radionuclide therapy (PRRT) with the somatostatin 
analogue octreotide. The hypothesis was that radiolabelled octreotide, that is used in scintigraphy with 
a low radioactive dose, could be used for PRR T when given with a high radioactive dose, which was 
tested in a rat model (chapter 4). 
In chapter 3 the effect of the somatostatin analogue octreotide on the growth of tumours in the 
rat liver is described. Octreotide, administered intravenously, inhibits the growth of tumours in the 
liver after direct injection of somatostatin receptor-positive hlmour cells into the portal vein. The 
growth of tumours in the liver after administration of somatostatin receptor-negative hlmour cells was 
not inhibited. Since we also demonstrated that the semm levels of circulating hormones and growth 
factors, which could be mediators for tumour growth, was not influenced by treatment with octreotide, 
a direct mechanism for the anti tumour effect was suggested. Since no effect of octreotide treatment 
was found for somatostatin receptor-negative tumours this direct effect might be mediated via a 
somatostatin receptor-dependent mechanism. 
Chapter 4 describes the antiproliferative effect of PRRT with radiolabelled octreotide in our 
rat liver metastases mode1. In a similar model as described in chapter 3 tumour growth was inhibited 
by PRRT when somatostatin receptor-positive tumour cells were used. The effects of PRRT are 
impressive compared to the effect of non-radioactive octreotide. We were able to demonstrate the 
necessity of the somatostatin receptor for this effect since pre-blocking with non-radioactive 
octreotide, leading to saturation of the receptors annihilated this effect. Moreover, no effect was found 
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when somatostatin receptor-negative tumour cells were used. Our data suggest that PRRT with 
radiolabelled octreotide could be a new promising treatment modality for patients with neuroendocrine 
tumours and other somatostatin receptor-positive tumours. 
In chapter 5 the results are described of different treatment schedules of PRRT with 
radiolabelled octreotide. The radioactive dose of 370 MBq as was also used in the experiments in 
chapter 4 appeared to be most effective. With this dose no severe toxicity was noted. PRRT was also 
effective when tumours were allowed 12 days to settle in the liver. Multiple dose treatment was more 
effective than single dose treatment. 
Chapter 6 gives an overview on the putative tumour growth stimulating effect of partial 
hepatectomy (PHx). PHx is the only curative treatment for patients with primary or secondary tumours 
in the liver. However the high number of early recurrences suggests that PHx might act as a "double-
edged sword". On one hand survival after PHx is increased but on the other hand PHx might enhance 
tumour growth. Several explanations for this phenomenon are described but most likely growth factors 
that orchestrate the process of liver regeneration after PHx are responsible for tumour growth 
stimulation. Options for adjuvant treatment after PBx are limited since systemic chemotherapy might 
also influence liver regeneration. TNF-a could be a treatment option since TNF-a is known to 
stimulate rather than inhibit liver regeneration. Treatment with octreotide and radiolabelled octreotide 
could provide a therapeutic option if liver regeneration is not affected. 
Chapter 7 describes the effects of PI-Ix on tumour growth in our liver metastases model. We 
designed a rat model in which tumour cells are injected into the portal vein during vascular occlusion 
of one or more liver lobes. Resection of 35 per cent of the liver induced a significant increase in 
tumour growth of somatostatin receptor-negative tumours whereas resection of 70 per cent provoked 
excessive tumour growth leading to more than 100 liver metastases and a significantly increased wet 
liver weight in all animals. This means that tumour growth stimulation is proportional to the extent of 
the resection. TNF-a, given intravenously, only had a marginal effect in rats that did not undergo PHx 
but was very effective after PI-Ix. However the clinical use of TNF-a is limited to isolated perfusion 
because of severe systemic toxicity. 
In chapter 8 the effect of octreotide and PRRT with radiolabelled octreotide on hlmour 
growth after partial hepatectomy is described. The first finding in these experiments is that also the 
growth of somatostatin receptor-positive tumours is stimulated by PHx. Treatment of somatostatin 
receptor-positive tumours with non-radiolabelled octreotide after PI-Ix did not decrease this tumour 
gro\\·'1h stimulation. After PRRT with radiolabelled octreotide, however, both in sham operated and 
131 
PHx animals there were only few somatostatin receptor-positive tumour colonies present while control 
animals all had a large tumour burden in their livers. PRRT was also effective on somatostatin 
receptor-negative tumours after PHx but not after sham operation. This effect on somatostatin 
receptor-negative tumours after partial hepatectomy was not expected. It was hypothesised that this 
effect ofPRRT could have been caused by influence on liver regeneration. Therefore we investigated 
the effect of PRRT on liver regeneration. Liver regeneration and liver function after PHx was not 
influenced by PRRT. This could imply that PRRT might be a safe treatment option after PHx 
clinically. 
For the optimal management of patients with neuroendocrine tumours accurate imaging and 
staging is essential. Somatostatin receptor scintigraphy (SRS) is a visualisation technique which has 
shown to localise neuroendocrine tumours with high sensitivity. The aim of the study described in 
chapter 9 was to compare the value of conventional imaging methods and SRS in the detection of 
both intra- and extrahepatic metastases in 48 patients with liver metastases of neuroendocrine tumours. 
Conventional imaging consisted of CT of chest and abdomen and ultrasound examination of upper 
abdomen in all patients and additional bone scintigraphy and colonoscopy in a few patients. SRS 
consisted of planar scintigraphy which yields whole body, one dimensional imaging in all patients and 
in 26 patients additional SPECT imaging in which a rotating camera is used to make reconstructions 
similar to CT. All conventional imaging methods together detected extrahepatic metastases in 22 of 
the 48 patients. SRS detected extrahepatic metastases in all of these 22 patients but also in 15 
additional patients. SRS detected 128 % more extrahepatic tumours in these patients that conventional 
imaging methods. With the addition of SPECT imaging to planar SRS liver metastases were detected 
in all patients. Therefore were conclude that SRS with the addition of SPECT imaging should be 
recommended as the first imaging method for the staging of patients with neuroendocrine tumours. 
Our paper demonstrates that nearly all patients with liver metastases of neuroendocrine tumours have 
extrahepatic metastases and are therefore excluded for curative liver surgery. Systemic PRRT with 
radiolabelled somatostatin analogues for these patients could be a promising treatment modality. 
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Conclusions 
I. Octreotide inhibits the growth of somatostatin receptor-positive tumours and not of somatostatin 
receptor-negative tumours in a liver model in the rat. 
2. PRRT with radiolabelled octreotide has an impressive inhibiting effect on the growth of 
somatostatin receptor-positive tumours in the rat. 
3. The effect ofPRRT is mediated through the somatostatin receptor since no effect is found after 
blocking of the somatostatin receptors. Moreover, no effect is found with PRRT on somatostatin 
receptor-negative tumours. 
4. PRRT can be effective on established tumours since also tumour growth was inhibited when 
treatment was given 12 days after tumour cell inoculation. 
5. Resection of 35 per cent or 70 per cent of the liver volume induces tumour growth stimulation in 
the regenerating remnant liver in the rat. 
6. The extent of tumour growth stimulation after partial hepatectomy is proportional to the volume of 
the liver that is resected. 
7. Tumour growth stimulation after 70 per cent hepatectomy in the rat is reduced by systemic 
treatment with TNF- Q. 
8. PRRT inhibits the grmvth of tumours in the liver even under tumour growth stimulating conditions 
caused by 70 per cent hepatectomy. This effect is at least partially not receptor-mediated since 
also tumour grO\vth inhibition was found for somatostatin receptor-negative tumours after partial 
hepatectomy. 
9. PRRT \",ith radiolabelled octreotide does not influence liver regeneration after 70 per cent 
hepatectomy in the rat. 
10. Somatostatin receptor scintigraphy in superior to all conventional imaging methods together in the 
imaging and staging of patients with neuroendocrine tumours. 
11. Of the patients with liver metastases 78 per cent also have extrahepatic metastases and are 
therefore excluded from curative liver resection. These patients could possibly benefit from 
PRRT. 
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Sam en vatting 
Doe! van dit proefschrift was om een nieuwe behandeling van tumoren te onwikkelen waarbij 
gebruik gemaakt wordt van radioactief octreotide. Met behulp van een rattenmodel wilden wij tevens 
aantonen dat tumorgroei wordt gestimuleerd door !everregeneratie die optreedt na resectie van een 
deel van de lever. Indien deze tumorgroei-stimulatie tijdens ieverregeneratie kon worden aangetoond 
wilden wij bestuderen of behandeling met octreotide en radioactief octreotide deze 
tumorgroeistimulatie kan belnvloeden. 
Het tweede doe! van dit proefschrift was om de aamullende waarde van somatostatinereceptor 
scintigrafie aan te tonen bij de diagnostiek van patienten met levermetastasen van neuro-endocrien 
tumoren. Somatostatinereceptor-scintigrafie is een techniek die, met behu!p van een lage dosis 
radioactief octreotide, tumoren kan afbeelden die specifieke somatostatinereceptoren tot expressie 
brengen. De belangrijkste groep tumoren die deze receptoren dragen zijn neuro-endocrien tumoren. 
Met behulp van somatostatinereceptor-scintigrafie kan men patienten selecteren die in aanmerking 
komen voor behandeling met octreotide en radioactief octreotide. 
Hoofdstuk 2 geeft een overzicht van het voorkomen van somatostatinereceptoren bij neuro-
endocrien tumoren en het gebruik van somatostatinereceptor-scintigrafie bij patienten met neuro-
endocriene aandoeningen. Beschreven wordt hoe somatostatine-analoga zoals octreotide klinisch 
worden gebruikt in de behandeling van neuro-endocrien ziekten en het effect dat deze somatostatine-
analoga hebben op de groei van tumoren. Het principe van peptide receptor radionuclide therapy 
(PRR T) met radioactief octreotide wordt beschreven. Het is onze hypothese dat radioactief octrcotide, 
dat in een laag radioactieve dosis wordt gebruikt voor scintigrafie, in een hoog radioactieve dosis kan 
worden gebruikt voor PRRT. 
In hoofdstuk 3 wordt het effect beschreven van het somatostatine-analogon octreotide op de 
groeJ van tumoren in de lever bij de rat. Octreotide remt de groei van tumoren die 
somatostatinereceptoren tot expressie brengen. Bij hlmoren die deze receptoren niet hebben remt 
octreotide de groei niet. Wij konden aantonen dat door behandeling met octreotide de waarde in het 
serum van enkele groeiregulerende hormonen niet veranderde waannee een direct effect op de 
tumorcellen van octreotide aanncmelijk werd gemaakt. Omdat er geen effect werd gevonden bij 
receptor-negatieve tumoren menen wij dat directe effect van octreotide afhankelijk is van de 
aanwezigheid van specifieke somatostatinereceptoren. 
Hoofdstuk 4 beschrijft het tumorgroei remmend effect van PRRT met radioactief octreotide in 
ons levennetastase model. PRRT was zeer effectief bij somatostatinereceptor-positieve tumoren. De 
resultaten waren indrukwekkend beter dan in de experimenten met niet-radioactief octreotide zoals 
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beschreven in hoofdstuk 3. Wij konden aantonen dat de aanwezigheid van somatostinereceptoren 
noodzakelijk is voor dit effect doordat blokkeren van de receptoren het effect van radioactief 
octreotide vrijwel volledig te niet deed. Tevens werd geen effect gezien van behandeling met 
radioactief octreotide bij somatostatinereceptor-negatieve tumoren. Gesteund door onze bevindingen 
zou PRRT met radioactief octreotide een veelbelovende behandelingsmogelijkheid kunnen zijn voor 
patienten met neuro-endocrien tumoren en andere receptor-positieve tumoren. 
In hoofdstuk 5 worden de resultaten besproken van experimenten waarin PRRT met 
radioactief octreotide wordt toegepast in verschillende doseringen van radioactiviteit en volgens 
verschillende behandel schemata. PRRT met indium gelabeld octreotide met een dosering van 
370MBq, zoals gebruikt in de experimenten in hoofdstuk vier bleek, het meest effectief. Met deze 
dosering werden geen bijwerkingen gevonden van PRRT. Herhaalde behandelingen waren effectiever 
dan een eenmalige behandeling. 
Hoofdstuk 6 geeft een overzicht van literatuur over en inzichten in het groeistimu1erend effect 
dat op kan treden tijdens leverregeneratie na resectie van een deel van de lever. Deze operatie, waarbij 
tumoren in de lever \vorden venvijderd met mede nemen van gezond lever weefsel, wordt partiele 
hepatectomie (PHx) genoemd. PHx is de enige behandelingsmogelijkheid met kans op genezing bij 
patienten met primaire levertumoren of levennetastasen van andere maligne aandoeningen. De 
overleving van patienten wordt door de operatie duidelijk verhoogd maar indien zich recidief 
tumorgroei ontwikkelt wordt dit bij het merendeel van de patienten a1 gediagnostiseerd binnen een jaar 
na de operatie. De meeste recidieven worden gevonden in de lever zeIf. PHx zou dus kunnen werken 
als een 'mes dat aan twee kanten snijdt'. Aan de ene kant verbetert de overleving door de operatie 
maar aan de andere kant lijkt het dat tumorgroei wordt gestimuleerd in de regenererende lever. Er zijn 
verschillende verklaringen voor versterkte tumorgroei na PHx. De meeste waarde wordt gehecht aan 
de verklaring dat groeifactoren die betrokken zijn bij het regeneratieproces van de lever tevens een 
tumorgroei-stimulerende werking hebben. Mogelijkheden voor adjuvante behande1ing direct na PHx 
worden beperkt doordat chemotherapie de regen era tie kan ontregelen. Behandeling met tumor necrosis 
factor a (TNF-a) zou een optie kunnen zijn direct na PHx omdat TNF-a de leverregeneratie zou 
stimuleren. Ook behandeling met octreotide of PRRT met radioactief octreotide zouden effectief 
kunnen zijn als adjuvante behandeling na PHx. Indien er tumorgroei-remming gevonden wordt dient 
tevens het effect van deze stoffen op het proces van leverregeneratie onderzocht moeten worden. 
Hoofdstuk 7 beschrijft het effect van PHx op de groei van tumoren in ons lever model. 
Resectie van 35 procent van de lever veroorzaakte een significante toename in het aanta1 
somatostatinereceptor-negatieve tumoren. Resectie van zeventig procent veroorzaakte een explosieve 
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tumorgroei waarbij in aIle dieren meer dan 100 tumoren werden gevonden in de lever. Tevens werd 
een significante toename gevonden van het gewicht van de levers. Hieruit conc1uderen wij dat de 
omvang van het tumorgroei-stimulerend-effect gerelateerd is aan de grootte van de leverresectie. 
Behandeling met TNF-a bleek het effect van tumorgroei stimulatie door PHx te kunnen remmen. 
Klinisch worden de mogeJijkheden van systemische toediening van TNF-a beperkt door ernstige 
toxiciteit. Wei wordt TNF-a gebruikt bij gei"soleerde perfusie van extremiteiten en solide organen. 
In hoofdstuk 8 wordt het effect beschreven van behandeling met octreotide en PRRT met 
radioactief octreotide op tumorgroei na PHx. Aangetoond werd dat ook somatostatine-receptor-
positieve tumoren tot versnelde groei komen tijdens leverregeneratie. Behandeling met niet-radioactief 
octreotide had geen invloed op de tumorgroei stimulatie van PHx. PRRT met radioactief octreotide 
resulteerde in een significant venninderde tumorgroei na PHx en controle operatie zoals beschreven in 
hoofdstuk 4 en 5. Tegen de verwachting in werd ook de groei geremd van receptor-negatieve hlmoren 
na PHx. Wij hadden de theorie dat de verminderde tumorgroei stimulatie van PHx veroorzaakt zou 
kunnen worden door remming van de leverregeneratie. In onze experimenten werd geen invloed 
worden aangetoond van PRRT op de leverregeneratie. Het feit dat de regeneratie niet wordt geremd 
door PRRT kan betekenen dat PRRT veilig kan worden toegepast direct na leverresectie. 
Om patienten met neuro-endocriene tumoren effectief te kunnen behandelen is het 
noodzakelijk om over goede diagnostiek te beschikken om te komen tot de juiste stagering. 
Somatostatinereceptor-scintigrafie (SRS) is een afbeeldingtechniek waannee neuro-endocrien 
tumoren, met hoge sensitiviteit, kunnen worden afgebeeld. Het doel van de studie in hoofdstuk 9 was 
om de waarde van de SRS te vergelijken met conventionele diagnostiek in de detectie van metastasen 
binnen en buiten de lever in 48 patienten met levennetastasen van histologisch bewezen neuro-
endocrien tumoren. Conventionele diagnostiek bestond uit CT en echo van de buik, eventueel 
aangevuld met een botscan of colonoscopie. Bij aIle patienten werd SRS als eendimensionaal 
onderzoek verricht. Bij 26 patienten werd dit onderzoek uitgebreid met SPECT afbeelding waarbij met 
scintigrafie-beelden reconstructies worden gemaakt zoals bij spiraal-CT afbeeldingen. Met 
conventionele diagnostiek werden in 22 van de 48 patienten metastasen gevonden buiten de lever. 
SRS bevestigde deze metastasen buiten de lever bij aile 22 patienten maar detecteerde deze bij nog 
eens 15 andere patienten. Met SRS werden 128 procent meer metastasen gevonden buiten de lever. 
Met de toevoeging van SPECT werden aIle patienten de aanwezigheid van levermetastasen bevestigd. 
Wij conc1uderen daarom dat bij aIle patienten met neuro-endocrien tumoren eerst SRS moet worden 
verricht en dan pas conventionele diagnostiek op indicatie. Wij von den dat bijna aIle patienten die 
levennetastasen hebben van neuro-endocrien tumoren ook metastasen hebben buiten de lever. 
Hierdoor komen deze patienten niet in aanmerking voor lever resectie met kans op genezing. PRRT 
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met radioactieve somatostatine-analoga zou voor deze patienten een vee1belovende 
behandelingsmogelijkheid kunnen zijn. 
Conclusies 
1. Behandeling met octreotide remt de groei van somatostatinereceptor-positieve tumoren in de rat 
en niet van receptor-negatieve tumoren. 
2. PRRT met radioactief octreotide resulteert in een indrukwekkende groeidaling van receptor-
positieve tumoren in de rat. 
3. Voor het effect van PRRT is de aanwezigheid van specifieke somatostatine receptoren 
noodzakelijk omdat blokkering van deze receptoren het effect van PRRT te niet doet. Daarnaast 
wordt geen effect gevonden bij receptor-negatieve tumoren. 
4. PRRT is effectiefin de vroege fase van tumorgroei in de lever, ook bij solide tumoren die zich 
gedurende 12 dagen hebben ontwikkeld. 
5. Resectie van 35 of70 procent van het levervolume resulteert in versterkte tumorgroei in de 
regenererende restlever. 
6. De intensiteit van tumorgroei-stimulatie is afhankelijk van de uitgebreidheid van de resectie. 
7. Tumorgroei-stimulatie na 70 procent partiele hepatectomie kan worden geremd met systemisch 
toegediend TNF -cr. 
8. PRRT met radioactief octreotide remt de groei van tumoren in de lever zelfs onder condities van 
tumorgroei-stimulatie door 70 procent partiele hepatectomie. Dit effect is ten dele niet receptor 
afhankelijk omdat na partiele resectie ook tumorgroei-remming werd gezien bij receptor-negatieve 
tumoren. 
9. PRRT met radioactief octreotide heeft geen invloed op leverregeneratie bij de rat. 
10. Somatostatine-receptor-scintigrafie heeft een grotere sensitiviteit dan conventionele diagnostiek 
bij de detectie en stagering van patienten met neuro-endocriene tumoren. 
11. Zevenentachtig procent van de patienten met levennetastasen van neuro-endocrien tumoren heeft 
ook metastasen buiten de lever en komt daarvoor niet in aanmerking voor curatieve leverresectie. 
Deze patienten zouden mogelijk baat hebben bij een behandeling met PRRT. 
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CHAPTER 11 
FUTURE ASPECTS OF PEPTIDE RECEPTOR 
RADIONUCLIDE THERAPY 
Introduction 
Based on the concept of somatostatin receptor scintigraphy with radio labelled peptides our 
experiments on peptide receptor radionuclide therapy (PRRT) were initialised, This thesis has 
demonstrated the possibilities for PRRT with the radiolabelled somatostatin analogue C1IIn_ 
DTPAo]octreotide. Our experimental results and also clinical findings indicate that PRRT with 
radiolabelled somatostatin analogues could be a promising new treatment modality for patients with 
somatostatin receptor-positive tumours. PRRT, however, is still in its infancy and further 
developments are necessary to optimise therapy. 
New radionuclides 
For radiotherapeutic applications, besides 111In other radionuclides such as 90y (yttrium) and 
177Lu (Lutetium) have also been proposed for coupling to somatostatin analogues. 9Dy , with a half-life of 
2.7 days, is a pure high-energy 13 emitter with a tissue range up to 12 nun, and 177Lu, with a half-life of 6.7 
days emits y radiation (suitable for visualisation), and intermediate-energy 13 particles with approximately 
2 nun tissue penetration. For tumours with a heterogeneous distribution of somatostatin receptors, 90y_ 
and I77Lu_Iabelled somatostatin analogues might have extra beneficial properties because of an effect 
known as "cross-fire". A tumour cell lacking somatostatin receptors might be hit by an electron coming 
from a neighbouring cell that has internalised the radio ligand. This mechanism may lead to a higher and 
more homogeneous radiation dose in larger parts of the tumour. 
Promising results with regard to growth inhibition were shown in pre-clinical studies with 
eradication of CA-20948 tumours1,2 and in patient studies using eOY-DOTAO,Tyr]octreotide 
(OctreoTher*). Preliminary clinical reports indicate that relatively high activities of [90y _ 
DOTAo,Tyr3]octreotide can be administered with low risk of myelotoxicity, although the radiation 
doses to the kidneys require careful consideration. Tumor doses can be high enough to obtain 
objective therapeutic responses3-5. 
High radiotherapeutic efficacy of PRRT with C77Lu-DOTAO,Tyr3]octreotate was found in 
experimental studies6• [ 177Lu-DOTAO,Tyr3]octreotate shows the highest tumour uptake of all tested 
octreotide analogues so far, with excellent tumour to kidney ratios. PRRT with this analogue started 
only very recently in our centre 7. 
New somatostatin analogues 
Currently the most promising somatostatin analogue is [Tyr3 ]octreotate, where the alcohol 
Thr( 01) at the C-terminus is replaced with the natural amino acid Thr. This analogue has a very high 
affinity for the somatostatin receptor subtype2 (ssh) and showed the highest CA-20948 tumour uptake 
in a biodistribution study in rats comparing different lllIn-labelled somatostatin analogues8• 
Reduction of toxicity 
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A major problem in PRRT is caused by the uptake of radioactivity in the kidneys: small 
peptides in the blood plasma are filtered through theglomerular capillaries in the kidneys and 
subsequently reabsorbed by and retained in the proximal tubular cells. Renal uptake of radioactivity 
can be reduced by 40 per cent by intravenous administration of a combination of L-Iysine and L-
arginine. Clinnically PRRT with somatostain analogues should be carried out with co-infusion of these 
aminoacids7. Other methods to reduce toxicity are currently under investigation. Another critical organ 
is bone marrow. Based on dosimetry ( for PRRT with IllIn or 177Lu with conventional gamma cameras 
and for PRRT with 90y with position emission tomography (PET) using S(y) the cumulative radiation 
dose has to be kept below 2-3 Oy. Higher doses may result in myelodysplasic syndrome andlor leukemia. 
Coupling to chemotherapeutic agents 
Another approach in treating tumours expressing somatostin receptors is to substitute the 
radionuclide with a chemotherapeutic agent. Schally's group has developed a cytotoxic somatostatin 
analogue containing 2 pyrrolino-doxorubicin (AN-20l), which is 500 to 1000 times more potent in 
vitro than its parent compound9,1O. By linking AN-201 to RC-121, a somatostatin analogue, a new 
cytotoxic somatostatin analogue, (AN-238), was obtained. Various in vitro experiments with AN-238 
on human and rat somatostatin receptor-positive tumours have shown effective inhibition of tumour 
growth I 1,12. 
Translection 0/ somatostatin receptors 
New developments in molecular biology have made it possible to transfect somatostatin 
receptor-negative tumour cells with a somatostatin receptor gene. Susini's group has developed an 
approach using somatostatin receptor subtype 2 (sst2) -gene transfer for the treatment of pancreatic 
cancerl3. By inducing the somatostatin receptor on these tumour cells, anti tumour effects were 
obtained which might be attributed to several mechanisms. First, an autocrine negative feedback loop 
in which transfected tumour cells start to produce somatostatin, which binds in an autocrine manner to 
the induced somatostatin receptor, may provide an inhibitory effect on tumour cell growth. Second, 
binding of somatostatin to sst2 upregulates p27, a tumour suppressor gene, which leads to cell cycle 
arrest in the 00-01 phase, and subsequently causes apoptosis. Local and distant bystander effects have 
also been noted. The local bystander effect might be attributed in part to apoptosis. When ssh-positive 
cells undergo apoptosis, these cells release apoptotic vesicles and enzymes, which in tum might kill 
neighbouring cells. The distant bystander effect may be explained on a paracrine effect. Somatostatin 
can upregulate the expression of sst) on parental tumour cells, thereby rendering them sensitive to the 
antiproliferative effect of somatostatin. All the above mentioned mechanisms may contribute to 
successful treatment of certain types of cancers with gene therapy. 
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Another reason why transfection of tumour cells with a somatostatin receptor gene may be 
beneficial involves peptide receptor radionuc1ide therapy (PRRT). By inducing the somatostatin 
receptor on somatostatin receptor~negative tumours, treatment with radionuc1ides might become an 
option. Moreover, transfection of somatostatin receptor~positive tumours with a somatostatin receptor 
gene can increase the homogeneity of distribution of tumour cells expressing the somatostatin receptor 
and so increase the efficacy ofPRRT. 
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DANKWOORD 
Ver in de vorige eeuw ben ik begonnen met wetenschappelijk onderzoek, hetgeen nu wordt 
afgesioten met dit proefschrift. Aanvankelijk leek het ontwikkelen van een nieuw rattenmodel een 
moeilijk te nemeo horde. Het heeft ruim een jaar geduurd tot het model geperfectioneerd was. Door 
samenwerking met de afdelingen Inwendige Geneeskunde en Nudeaire Geneeskunde zijn uiteindelijk 
mooie dingen tot stand gekomen. Ik hoop dat dit proefschrift, dat gebaseerd is op pre-klinisch 
onderzoek, kan dienen als basis voor het verder ontwikkelen van peptide receptor radionuclide 
therapie bij patienten. 
In mijn lange bestaan als wetenschapper heb ik, onder andere, van onderstaande personen veel 
ondersteuning gehad. 
Dr. R.L. Marquet: Richard, van jou heb ik de meeste steun gekregen. Gedurende aIle acht jaren heb jij 
geloofd dat het boek er zou komen, ook toen ik daar zelf geen heil meer in zag. Jij ontving mij altijd 
weer even hartelijk en hoopvol wanneer ik na lange tijd mijn neus weer eens liet zien op het lab. Door 
met jou te praten over wetenschap, het leven en flauwekul is meer dan aIleen dit boek gevonnd. 
Dr. CNJ. van Eijck: Co-promotor Cas, jij bent de grote stimulator. Door jouw vennogen om 
multidisciplinair te werken is dit werk tot stand gekomen. Hoofdschuddend heb jij je gebogen over 
mijn stukken en ze klinisch verantwoord gemaakt. Jouw ondersteuning aan wetenschappers en met 
name jouw betrokkenheid bij de patientenzorg zijn mij tot voorbeeld. 
Dr. W.A.P. Breeman: Tutor Wout,jij hebt mij ingewijd in een geheel nieuw vakgebied. Jouw 
nuchterheid en humor zorgden immer voor een aangenaam verblijf op de nuc1eaire. Ik had alleen 
gehoopt dat je tekstueel minder streng zou zijn. 
Profdr. J. Jeekel: Mijn eerste promotor, u wil ik bedanken voor het in mij gestelde vertrouwen. Ik wil 
u tevens bedanken voor het feit dat u mij - niet alleen wetenschappelijk - wei eens de hand boven het 
hoofd heeft gehouden. 
Prof dr. EP.Krenning: Mijn tweede promotor, peptide receptor radionuclide therapie is uw 
geesteskind. Immer wanneer ik wilde praten over rat experimenten werd ik volledig meegetrokken in 
verhandelingen over gunstige klinische resultaten. Hierdoor bleef ik gemotiveerd om de zoveelste 
revisie van de manuscripten door te voeren. Door de inzet van u en uw vakgroep zal de toekomst voor 
bepaalde groepen patienten er bestist rooskleuriger uitzien. 
Prof dr. N W. Tilanus en Profdr. Th. van der Kwast: Ik wi! u bedanken voor het zorgvuldig 
doomernen van het manuscript en uw bereidheid om deel uit te maken van de promotiecommissie. 
Profdr. S. WJ. Lamberts: Door de inzet en kennis van u en uw medewerkers is het belang van 
receptoren voor peptide honnonen wereldwijd bekend geworden. Ik waardeer het enonn dat u zitting 
wilt nemen in de promotiecommissie. 
Dr. J.N.M !Jzermans: Jan, jij hebt mij in 1992 aangenomen voor een jaar wetenschap en mij bij mijn 
eerste pogingen tot schrijven zwaar ondersteund. De Schoemakerprijs 1995 komt mede jou toe. 
Dr. DJ Kwekkeboom: Dik,jouw bijdrage aan het schrijven van het klinische deel van mijn 
proefschrift was onmisbaar. 
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Dr. L.J Hofland: Leo, dank voor de bepalingen en de reflectie. 
Drs. A.G.J Aalbers en Drs. A. Mearadji: Arend en Amir, beste SIO's, jul1ie hebben mij, als trouwe 
honden, sportief en wetenschappelijk ondersteund. Ik ben er van overtuigd dat ook jullie het 
onderzoek met een promotie zuHen afsluiten. Ik geefhet klinisch en wetenschappelijk vaandel graag 
aan jullie over. 
Drs. CA.H. Hiemstra en Drs. S W.A. Nij Bijvank: Coen en Bas, hartelijk dank voor de uren die jullie 
vrijgemaakt hebben naast de studie. 
Drs. C Verhoef en Dr. JH. W. de Wilt: Kees en Hans, wat ben ik blij dat er af en toe vrienden waren 
die mij achter m'n computer vandaan wisten te sleuren. Handicapverrekening is een zegen. 
Ron, Fred, Ieneke, Wil, Pim, dierverzorgers en aUe anderen van he! chirurgisch lab: bedankt voor de 
prettige en langdurige samenwerking en v~~r de verzorging van de dieren. 
Mw. S. van Belle: Editor Scarlet, bedankt voor alje inspanningen. Door jouw inbreng is deze zware 
materie enigszins leesbaar geworden. 
Dr. E.M. Manusama: Paranimf Eric, als jonge honden zijn wij samen begonnen op het lab. Ik vind het 
fijn dat je nu bij de afsluiting aan mijn zijde wilt staan. 
AUe knaagdieren in de wereld: Ik ben een zondaar maar ik deed het met een oprecht hart. 
Pap, Mam en Babber: Jullie hebben mij de basis gegeven waardoor dit alles mogelijk is geworden. 
Mw. Dr(s). C W. Paquin e. v. Sloater: Chrissie, jij maakt de offers en ik ga maar door. Door jouw 
moedige beslissing om te stoppen met de opleiding hebben wij een harrnonieus gezin. Al16 jaar gaan 
wij zij aan zij. Datjij nu ook aan mijn zijde gaat als paranimfis een logische keus. Over een paar 
maanden zal ik trots aanjouw zijde staan wanneer jij promoveert. "Ik ben nergens goed voor, maar dat 
wist jij al heel lang. Maar ik kan van je houden zoals niemand anders kan." 
Floor en Lotte: Papa is eindelijk klaar met z'n boek dus meer tijd om te spelen en te knuffelen. Jullie 
maken mijn leven tot een groot feest. De computer is van nu af aan gewoon weer voor spelletjes. 
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APUD 
Bmax 
BIM 23014 
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CT 
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DOTA 
DTPA 
EGF 
FCS 
FGF 
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GBq 
GEP 
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HGF 
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IFN 
IGF-l 
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MMC 
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PHx 
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RNA 
RT-PCR 
SPECT 
SRS 
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SS-R 
sst 
TGF 
TNF 
US 
WAG 
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Amine precursor uptake and decarboxylation 
Maximum binding capacity 
Lanreotide 
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Computed tomography 
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Epidennal growth factor 
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Hepatocyte growth factor 
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Insulin-like growth factor-l 
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Magnetic resonance imaging 
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Position emission tomography 
Partial hepatectomy 
Peptide receptor radionuclide therapy 
Vaptreotide 
Reticulo endothelial system 
Ribonucleic acid 
Transcriptase polymerase chain reaction 
Single photon emission computed tomography 
Somatostatin receptor scintigraphy 
Somatostatin 
Somatostatin receptor 
Somatostatin receptor subtype 
Transforming growth factor 
Tumour necrosis factor 
Ultra sound 
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